EP1250431A2 - Modulation of gene expression in formation of fatty atherosclerotic lesions - Google Patents
Modulation of gene expression in formation of fatty atherosclerotic lesionsInfo
- Publication number
- EP1250431A2 EP1250431A2 EP01905039A EP01905039A EP1250431A2 EP 1250431 A2 EP1250431 A2 EP 1250431A2 EP 01905039 A EP01905039 A EP 01905039A EP 01905039 A EP01905039 A EP 01905039A EP 1250431 A2 EP1250431 A2 EP 1250431A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- seq
- nucleic acid
- acid molecule
- isolated nucleic
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000014509 gene expression Effects 0.000 title claims description 247
- 230000003902 lesion Effects 0.000 title abstract description 64
- 230000003143 atherosclerotic effect Effects 0.000 title abstract description 39
- 230000015572 biosynthetic process Effects 0.000 title abstract description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 361
- 229920001184 polypeptide Polymers 0.000 claims abstract description 354
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 353
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 222
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 222
- 239000002157 polynucleotide Substances 0.000 claims abstract description 221
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 claims abstract description 177
- 238000000034 method Methods 0.000 claims abstract description 158
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 146
- 229960004294 lercanidipine Drugs 0.000 claims abstract description 135
- 230000001105 regulatory effect Effects 0.000 claims abstract description 61
- 229940127292 dihydropyridine calcium channel blocker Drugs 0.000 claims abstract description 7
- 239000002773 nucleotide Substances 0.000 claims description 170
- 125000003729 nucleotide group Chemical group 0.000 claims description 170
- 150000007523 nucleic acids Chemical class 0.000 claims description 129
- 102000039446 nucleic acids Human genes 0.000 claims description 125
- 108020004707 nucleic acids Proteins 0.000 claims description 125
- 102000004169 proteins and genes Human genes 0.000 claims description 77
- 238000011161 development Methods 0.000 claims description 65
- 230000000694 effects Effects 0.000 claims description 64
- 239000012634 fragment Substances 0.000 claims description 62
- 201000001320 Atherosclerosis Diseases 0.000 claims description 56
- 239000000523 sample Substances 0.000 claims description 55
- 150000001413 amino acids Chemical class 0.000 claims description 49
- 108020004414 DNA Proteins 0.000 claims description 45
- 238000011282 treatment Methods 0.000 claims description 42
- 239000013598 vector Substances 0.000 claims description 39
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 37
- 230000027455 binding Effects 0.000 claims description 35
- 238000009739 binding Methods 0.000 claims description 35
- 230000001575 pathological effect Effects 0.000 claims description 35
- 239000002299 complementary DNA Substances 0.000 claims description 34
- 230000004075 alteration Effects 0.000 claims description 28
- 238000003556 assay Methods 0.000 claims description 24
- 238000009396 hybridization Methods 0.000 claims description 21
- 230000004071 biological effect Effects 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 239000012472 biological sample Substances 0.000 claims description 18
- 230000007423 decrease Effects 0.000 claims description 14
- 230000035772 mutation Effects 0.000 claims description 14
- 102000053602 DNA Human genes 0.000 claims description 12
- 238000012217 deletion Methods 0.000 claims description 11
- 230000037430 deletion Effects 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 11
- 230000036961 partial effect Effects 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 238000004166 bioassay Methods 0.000 claims description 5
- 239000005022 packaging material Substances 0.000 claims description 5
- 230000033228 biological regulation Effects 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 150000002739 metals Chemical class 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 166
- 210000000709 aorta Anatomy 0.000 description 162
- 238000003752 polymerase chain reaction Methods 0.000 description 154
- 230000000260 hypercholesteremic effect Effects 0.000 description 108
- 239000000047 product Substances 0.000 description 108
- 241000283973 Oryctolagus cuniculus Species 0.000 description 89
- 210000004027 cell Anatomy 0.000 description 88
- 235000012000 cholesterol Nutrition 0.000 description 81
- 238000003757 reverse transcription PCR Methods 0.000 description 79
- 108020004999 messenger RNA Proteins 0.000 description 70
- 235000018102 proteins Nutrition 0.000 description 68
- 238000004458 analytical method Methods 0.000 description 67
- 125000003275 alpha amino acid group Chemical group 0.000 description 66
- 230000018109 developmental process Effects 0.000 description 62
- 235000001014 amino acid Nutrition 0.000 description 61
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 57
- 241001465754 Metazoa Species 0.000 description 50
- 230000003247 decreasing effect Effects 0.000 description 38
- 239000010432 diamond Substances 0.000 description 38
- 230000001965 increasing effect Effects 0.000 description 37
- 102100031437 Cell cycle checkpoint protein RAD1 Human genes 0.000 description 36
- 101001130384 Homo sapiens Cell cycle checkpoint protein RAD1 Proteins 0.000 description 36
- 239000000203 mixture Substances 0.000 description 36
- 210000001519 tissue Anatomy 0.000 description 33
- 201000010099 disease Diseases 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 28
- 239000003153 chemical reaction reagent Substances 0.000 description 28
- 241000282414 Homo sapiens Species 0.000 description 26
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 25
- 229940127291 Calcium channel antagonist Drugs 0.000 description 25
- 208000035475 disorder Diseases 0.000 description 25
- 108091028043 Nucleic acid sequence Proteins 0.000 description 24
- 108090000994 Catalytic RNA Proteins 0.000 description 21
- 102000053642 Catalytic RNA Human genes 0.000 description 21
- 235000005911 diet Nutrition 0.000 description 21
- 230000037213 diet Effects 0.000 description 21
- 108091092562 ribozyme Proteins 0.000 description 21
- 241000894007 species Species 0.000 description 21
- 230000000295 complement effect Effects 0.000 description 18
- 230000028993 immune response Effects 0.000 description 18
- 150000002632 lipids Chemical class 0.000 description 18
- ZDXUKAKRHYTAKV-MGBGTMOVSA-N 5-o-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] 3-o-methyl (4r)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-MGBGTMOVSA-N 0.000 description 17
- 230000014616 translation Effects 0.000 description 17
- 108091034117 Oligonucleotide Proteins 0.000 description 16
- 238000013519 translation Methods 0.000 description 16
- 108010076504 Protein Sorting Signals Proteins 0.000 description 15
- 210000000349 chromosome Anatomy 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 15
- 210000002540 macrophage Anatomy 0.000 description 15
- 238000012163 sequencing technique Methods 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 14
- 230000035755 proliferation Effects 0.000 description 14
- 238000006467 substitution reaction Methods 0.000 description 14
- 239000000427 antigen Substances 0.000 description 13
- 238000003776 cleavage reaction Methods 0.000 description 13
- 238000005755 formation reaction Methods 0.000 description 13
- 108020001507 fusion proteins Proteins 0.000 description 13
- 102000037865 fusion proteins Human genes 0.000 description 13
- 230000007017 scission Effects 0.000 description 13
- 239000000074 antisense oligonucleotide Substances 0.000 description 12
- 238000012230 antisense oligonucleotides Methods 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 230000003399 chemotactic effect Effects 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- -1 diltiazem) Chemical class 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 230000009870 specific binding Effects 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 230000004069 differentiation Effects 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 230000002163 immunogen Effects 0.000 description 10
- 230000002459 sustained effect Effects 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 9
- 230000035605 chemotaxis Effects 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 230000003827 upregulation Effects 0.000 description 9
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 8
- 239000000480 calcium channel blocker Substances 0.000 description 8
- 210000002889 endothelial cell Anatomy 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 206010003210 Arteriosclerosis Diseases 0.000 description 7
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- 230000000692 anti-sense effect Effects 0.000 description 7
- 208000011775 arteriosclerosis disease Diseases 0.000 description 7
- 210000001367 artery Anatomy 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000002759 chromosomal effect Effects 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 230000008929 regeneration Effects 0.000 description 7
- 238000011069 regeneration method Methods 0.000 description 7
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 description 6
- 102000007330 LDL Lipoproteins Human genes 0.000 description 6
- 102000004895 Lipoproteins Human genes 0.000 description 6
- 108090001030 Lipoproteins Proteins 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 210000001772 blood platelet Anatomy 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000003828 downregulation Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000013507 mapping Methods 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 238000003259 recombinant expression Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 4
- 108090000312 Calcium Channels Proteins 0.000 description 4
- 102000003922 Calcium Channels Human genes 0.000 description 4
- 239000004366 Glucose oxidase Substances 0.000 description 4
- 108010015776 Glucose oxidase Proteins 0.000 description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 4
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 210000001723 extracellular space Anatomy 0.000 description 4
- 229940116332 glucose oxidase Drugs 0.000 description 4
- 235000019420 glucose oxidase Nutrition 0.000 description 4
- 208000024908 graft versus host disease Diseases 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 230000015590 smooth muscle cell migration Effects 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 102000000018 Chemokine CCL2 Human genes 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108091060211 Expressed sequence tag Proteins 0.000 description 3
- 208000001860 Eye Infections Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000001388 Opportunistic Infections Diseases 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010240 RT-PCR analysis Methods 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 3
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000000923 atherogenic effect Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 210000003989 endothelium vascular Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 208000011323 eye infectious disease Diseases 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 210000000497 foam cell Anatomy 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000009395 genetic defect Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 230000002439 hemostatic effect Effects 0.000 description 3
- 239000012678 infectious agent Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 210000003041 ligament Anatomy 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 229940127240 opiate Drugs 0.000 description 3
- 229940005483 opioid analgesics Drugs 0.000 description 3
- 230000005298 paramagnetic effect Effects 0.000 description 3
- 230000007505 plaque formation Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000004853 protein function Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 230000002537 thrombolytic effect Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 101100230428 Caenorhabditis elegans hil-5 gene Proteins 0.000 description 2
- 208000004434 Calcinosis Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- WMFYOYKPJLRMJI-UHFFFAOYSA-N Lercanidipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 WMFYOYKPJLRMJI-UHFFFAOYSA-N 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000034827 Neointima Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 208000033464 Reiter syndrome Diseases 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 201000005485 Toxoplasmosis Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000037741 atherosclerosis susceptibility Diseases 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000002316 cosmetic surgery Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000002616 endonucleolytic effect Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001506 fluorescence spectroscopy Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 201000006592 giardiasis Diseases 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000002873 global sequence alignment Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 238000010185 immunofluorescence analysis Methods 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229910052738 indium Inorganic materials 0.000 description 2
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 229960002162 lercanidipine hydrochloride Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000002601 radiography Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 208000002574 reactive arthritis Diseases 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 208000006379 syphilis Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 1
- JKMPXGJJRMOELF-UHFFFAOYSA-N 1,3-thiazole-2,4,5-tricarboxylic acid Chemical compound OC(=O)C1=NC(C(O)=O)=C(C(O)=O)S1 JKMPXGJJRMOELF-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 102100025230 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial Human genes 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 241000203809 Actinomycetales Species 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 108010087522 Aeromonas hydrophilia lipase-acyltransferase Proteins 0.000 description 1
- 208000002004 Afibrinogenemia Diseases 0.000 description 1
- 208000008190 Agammaglobulinemia Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 102000018619 Apolipoproteins A Human genes 0.000 description 1
- 108010027004 Apolipoproteins A Proteins 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 241001112741 Bacillaceae Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 206010004053 Bacterial toxaemia Diseases 0.000 description 1
- 241000606126 Bacteroidaceae Species 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 241000702628 Birnaviridae Species 0.000 description 1
- 206010005098 Blastomycosis Diseases 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 241000714198 Caliciviridae Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000003732 Cat-scratch disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000606069 Chlamydiaceae Species 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 241001533399 Circoviridae Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 208000003495 Coccidiosis Diseases 0.000 description 1
- 201000003874 Common Variable Immunodeficiency Diseases 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 208000009514 Dourine Diseases 0.000 description 1
- 201000009084 Dysgammaglobulinemia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010014568 Empyema Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000186811 Erysipelothrix Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010016075 Factor I deficiency Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101100356020 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) recA gene Proteins 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 208000006968 Helminthiasis Diseases 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 230000010556 Heparin Binding Activity Effects 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000019758 Hypergammaglobulinemia Diseases 0.000 description 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 208000007746 Immunologic Deficiency Syndromes Diseases 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 208000004023 Legionellosis Diseases 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 208000000706 Leukocyte-Adhesion Deficiency Syndrome Diseases 0.000 description 1
- 102000011965 Lipoprotein Receptors Human genes 0.000 description 1
- 108010061306 Lipoprotein Receptors Proteins 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000712045 Morbillivirus Species 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 101100042680 Mus musculus Slc7a1 gene Proteins 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000204003 Mycoplasmatales Species 0.000 description 1
- 241000588656 Neisseriaceae Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000002774 Paraproteinemias Diseases 0.000 description 1
- 208000026681 Paratuberculosis Diseases 0.000 description 1
- 206010033971 Paratyphoid fever Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 241000029132 Paronychia Species 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 208000004666 Phagocyte Bactericidal Dysfunction Diseases 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 208000025237 Polyendocrinopathy Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 208000002787 Pregnancy Complications Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 208000031482 Prosthesis-Related Infections Diseases 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000606683 Rickettsiaceae Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710801 Rubivirus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
- 108010016797 Sickle Hemoglobin Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000029033 Spinal Cord disease Diseases 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000001117 Theileriasis Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 208000013222 Toxemia Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 206010063661 Vascular encephalopathy Diseases 0.000 description 1
- 206010054880 Vascular insufficiency Diseases 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000004618 arterial endothelial cell Anatomy 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000007657 benzothiazepines Chemical class 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 201000001383 blood group incompatibility Diseases 0.000 description 1
- 208000014759 blood platelet disease Diseases 0.000 description 1
- 208000016363 blood protein disease Diseases 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- OKLAEQBUDFSNDL-UHFFFAOYSA-N calcium;1,4-dihydropyridine Chemical compound [Ca].C1C=CNC=C1 OKLAEQBUDFSNDL-UHFFFAOYSA-N 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- BKHZIBWEHPHYAI-UHFFFAOYSA-N chloroform;3-methylbutan-1-ol Chemical compound ClC(Cl)Cl.CC(C)CCO BKHZIBWEHPHYAI-UHFFFAOYSA-N 0.000 description 1
- ZYWFEOZQIUMEGL-UHFFFAOYSA-N chloroform;3-methylbutan-1-ol;phenol Chemical compound ClC(Cl)Cl.CC(C)CCO.OC1=CC=CC=C1 ZYWFEOZQIUMEGL-UHFFFAOYSA-N 0.000 description 1
- 238000003200 chromosome mapping Methods 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 108091092330 cytoplasmic RNA Proteins 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 125000004427 diamine group Chemical group 0.000 description 1
- 201000004587 dientamoebiasis Diseases 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 230000009843 endothelial lesion Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 108010049074 hemoglobin B Proteins 0.000 description 1
- 201000001505 hemoglobinuria Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 125000001967 indiganyl group Chemical group [H][In]([H])[*] 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000001499 laser induced fluorescence spectroscopy Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000027928 long-term synaptic potentiation Effects 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 230000022275 macrophage chemotaxis Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000028550 monocyte chemotaxis Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 101150009573 phoA gene Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920000379 polypropylene carbonate Polymers 0.000 description 1
- 239000005373 porous glass Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000011354 prosthesis-related infectious disease Diseases 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 229940085239 selective calcium channel blockers with direct cardiac effects phenylalkylamine derivative Drugs 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 208000008776 trombiculiasis Diseases 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 208000023577 vascular insufficiency disease Diseases 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- Atherosclerosis is a disease-state in which the walls of the arteries become thickened and lose their elasticity, resulting in a decreased ability to pump blood to peripheral organs and withstand systemic pressure.
- the most common form of atherosclerosis is caused by the buildup of fatty deposits in the innermost layer of the artery wall.
- Another form of atherosclerosis Monckeberg's atherosclerosis, results from the build-up of calcium deposits that destroys the middle layer of the artery wall.
- Yet another form of the disease involves the destruction of the smaller arteries, or arterioles. All three forms of the disease contribute to a decreased blood flow to vital organs, which can lead to a stroke, heart attack, or kidney failure.
- the current identified risk factors for developing atherosclerosis include high blood pressure, increased plasma levels of low density lipoprotein, decreased plasma levels of high density lipoprotein, diabetes, obesity, and a genetic predisposition.
- the arterial wall is made up of three distinct layers: the intima, media, and adventitia.
- the innermost layer, the intima consists primarily of smooth muscle cells and a thin layer of endothelial cells which lines the lumen of the artery.
- the media is a region of elastic and collagen fibers containing, inter alia, smooth muscle cells, fibroblasts, and macrophages.
- the collagenous adventitia layer comprises the outer component of the arterial wall.
- Atherosclerotic lesions are characterized by numerous biochemical changes, including an increased number of cells, mainly macrophages and smooth muscle cells, in the intima and the appearance of macrophages filled with lipid droplets (foam cells).
- the presence of lipid deposits and other changes in the composition of the matrix disrupt the intimal architecture, resulting in intimal disorganization and the thickening and deformation of the arterial wall.
- atherosclerotic lesions result from specific cell reactions initiated by the accumulation of atherogenic, plasma-derived lipoproteins in the arterial intima. Lesion size and complexity increase as lipoprotein accumulation in the intima continues and increases.
- apolipoprotein B For example, increased levels of apolipoprotein B have been associated with a thickened intima in the aorta of swine (Hoff et al., Lab. Invest., 48:492-504 (1983)) and human distal abdominal aortas (Spring et al., Exp. Mol. Pathol, 51:179-185 (1989)).
- Lipoproteins may be trapped in the intima by matrix components and then undergo modification, including, for example, oxidation (Schwenke et al., Arteriosclerosis, 9:895-907 (1989); Schwenke et al., Arteriosclerosis, 9:908-918 (1989); Fry, D. L., Arteriosclerosis, 7:88- 100 (1987); Steinberg et al., JAMA, 264:3047-3052 (1990)).
- the modified lipoproteins may be internalized by macrophages and/or smooth muscle cells through native lipoprotein receptors or via a scavenger receptor pathway (Pitas, R. E., J. Biol. Chem., 265:12722-12727 (1989)).
- This movement may be a response to the increased presence of oxidized lipoproteins, which have been shown to be chemotactic for monocytes in vitro (Quinn et al., Proc. Nat'l. Acad. Sci., 84:2995-2998 (1987)).
- Injured or activated endothelial cells may also produce leukocyte adherence molecules and secrete cytokines, which are chemotactic for leukocytes and smooth muscles cells, as well as produce growth factors for all of the cell types on or within the arterial wall (Gajdusek et al., J. Cell Biol, 85:467-472 (1980)). These processes trigger a cascade of events leading to morphological changes in the vessel wall and the development of vascular diseases (Ross (1993), supra; Jackson, et al., Hypertension, 20:713-736 (1992); Popma et al., Circ, 84:1426- 1436 (1991)).
- platelet and/or fibrin deposits on the intima could initiate the development of atherosclerotic lesions.
- Several researchers have reported the microscopic observation of thin layers of fibrin and/or aggregated platelets on the endothelial surface of the intima (More et al., Arch. Pathol, 63:612-620 (1957); McMillan, G. C, Acta Cardiol, 11:43-62 (1965); Geer et al., Monogr. Atheroscler., 2:1-140 (1972); Spurlock et al., Scanning Microsc, 1 :1359-1365 (1987)).
- it is not known whether such deposits can enlarge to become lesions in the absence of risk factors that favor lipid deposition.
- calcium channel antagonists There are three subclasses of calcium channel antagonists: the phenylalkylamine derivatives (e.g. verapamil), the benzothiazepines (e.g. diltiazem), and the diydropyridines (e.g. nifedipine, lercanidipine). All three subclasses modify calcium entry into cells by interacting with specific binding sites on the ⁇ x ⁇ subunit of the L-type voltage-dependent calcium channel (Nayler (1993), supra).
- calcium antagonists have been shown to decrease the accumulation of collagen, elastin, and proteoglycans in the arterial wall, following administration of compounds that induce atherosclerosis (Walters et al., J. Am. Coll. Cardiol, 15:116A (1990)).
- lercanidipine A new dihydropyridine calcium antagonist, lercanidipine, has been shown to effectively reduce smooth muscle cell migration and proliferation in vitro (Corsini et al., J. Cardiovasc. Pharm., 28:687-694 (1996)).
- Lercanidipine has a high specificity for vascular smooth muscle cells and has a long duration of action due to its liposolubility.
- lercanidipine has been shown to modulate cholesterol acyl transferase activity and to act as an antioxidant for LDL in endothelial cell-mediated oxidation (Soma et al., Br. J. Pharm., 125:1471-1476 (1998)). Further in vivo studies have revealed that lercanidipine can inhibit both aortic fatty lesion deposition and carotid intimal hyperplasia (Soma (1998), supra).
- hyperlipidemia-induced atherosclerosis is also associated with altered gene expression that initiates cell proliferation and de- differentiation in the intima of the arterial wall.
- the differential expression of genes following atherogenic stimulus has been described in several cells, including endothelial cells (de Waard et al., Gene, 226:1-8 (1999); De Graba T. J., Neurology, 49:S15-S19 (1997)), smooth muscle cells (Sobue et al., Mol. Cell. Biochem., 190:105-118 (1999)) and macrophages (Chiu, D.S., Arterioscler. Thromb.
- genes whose level of expression is altered during the onset of atherosclerosis would not only contribute to the understanding of the disease pathology, but would also identify genes useful as diagnostic markers to indicate patients at risk for stroke or cardiovascular disease. Furthermore, the identification of differentially regulated genes would be useful to target genes for potential therapeutic intervention. In addition, the identification of genes whose expression is affected by calcium antagonists would advance the development of anti-atherosclerotic therapy that would target the specific action of calcium antagonists. The identification of such genes would also reveal key pathways that could be targeted for further investigation.
- the PCR-based Total Gene Expression (TOGATM) differential display system has been used to identify genes modulated during the development of atherosclerosis using an in vivo model wherein a fatty-streak lesion was induced in rabbit aorta.
- the TOGA system was used to study the effect of calcium antagonists, such as lercanidipine, on gene expression during fatty lesion development. Such studies are useful to determine the genes associated with the atherosclerotic phenotype and also those genes whose expression is affected by calcium antagonists. Such information can be used to identify proteins and genes that are useful in therapeutic and diagnostic applications in the treatment of atherosclerosis.
- the present invention provides novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant methods for producing the polynucleotides and the polypeptides.
- One embodiment of the invention provides an isolated nucleic acid molecule comprising a polynucleotide chosen from the group consisting of SEQ ID NO:l, SEQ ID NO:2, SEQ ED NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO.l l, SEQ ID NO:12, SEQ ID NO: 13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:
- an isolated nucleic acid molecule comprising a polynucleotide at least 95% identical to any one of these isolated nucleic acid molecules and an isolated nucleic acid molecule at least ten bases in length that is hybridizable to any one of these isolated nucleic acid molecules under stringent conditions. Any one of these isolated nucleic acid molecules can comprise sequential nucleotide deletions from either the 5 '-terminus or the 3 '-terminus. Further provided is a recombinant vector comprising any one of these isolated nucleic acid molecules and a recombinant host cell comprising any one of these isolated nucleic acid molecules. Also provided is the gene corresponding to the cDNA sequence of any one of these isolated nucleic acids.
- Another embodiment of the invention provides an isolated polypeptide encoded by a polynucleotide chosen from the group consisting of SEQ ID NO:l, SEQ ID NO:2, SEQ ED NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ D NO:9, SEQ ID NO: 10, SEQ ID NO:l l, SEQ JD NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ED NO:17, SEQ ID NO:18, SEQ ID NO: 19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ED NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ
- an isolated nucleic acid molecule encoding any of these polypeptides, an isolated nucleic acid molecule encoding a fragment of any of these polypeptides, an isolated nucleic acid molecule encoding a polypeptide epitope of any of these polypeptides, and an isolated nucleic acid encoding a species homologue of any of these polypeptides.
- any one of these polypeptides has biological activity.
- any one of the isolated polypeptides comprises sequential amino acid deletions from either the C-terminus or the N- terminus.
- a recombinant host cell that expresses any one of these isolated polypeptides.
- Yet another embodiment of the invention comprises an isolated antibody that binds specifically to an isolated polypeptide encoded by a polynucleotide chosen from the group consisting of SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:l l, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ED NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ JD NO:26, SEQ ID NO:27, SEQ D NO:28, SEQ ID NO:29, SEQ ED NO:30, SEQ ID NO:
- the isolated antibody can be a monoclonal antibody or a polyclonal antibody;
- Another embodiment of the invention provides a method for preventing, treating, modulating, or ameliorating a medical condition, such as atherosclerosis comprising administering to a mammalian subject a therapeutically effective amount of a polypeptide of the invention or a polynucleotide of the invention.
- a further embodiment of the invention provides an isolated antibody that binds specifically to the isolated polypeptide of the invention.
- a preferred embodiment of the invention provides a method for preventing, treating, modulating, or ameliorating a medical condition, such as atherosclerosis, comprising administering to a mammalian subject a therapeutically effective amount of the antibody.
- An additional embodiment of the invention provides a method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject.
- the method comprises determining the presence or absence of a mutation in a polynucleotide of the invention.
- a pathological condition or a susceptibility to a pathological condition, such as atherosclerosis is diagnosed based on the presence or absence of the mutation.
- Even another embodiment of the invention provides a method of diagnosing a pathological condition or a susceptibility to a pathological condition, such as atherosclerosis in a subject.
- the method comprises detecting an alteration in expression of a polypeptide encoded by the polynucleotide of the invention, wherein the presence of an alteration in expression of the polypeptide is indicative of the pathological condition or susceptibility to the pathological condition.
- the alteration in expression can be an increase in the amount of expression or a decrease in the amount of expression.
- a first biological sample is obtained from a patient suspected of having atherosclerosis and a second sample from a suitable comparable control source is obtained.
- the amount of at least one polypeptide encoded by a polynucleotide of the invention is determined in the first and second sample.
- the amount of the polypeptide in the first and second samples is determined.
- a patient is diagnosed as having atherosclerosis if the amount of the polypeptide in the first sample is greater than or less than the amount of the polypeptide in the second sample.
- Another embodiment of the invention provides a method for identifying a binding partner to a polypeptide of the invention.
- a polypeptide of the invention is contacted with a binding partner and it is determined whether the binding partner effects an activity of the polypeptide.
- Yet another embodiment of the invention is a method of identifying an activity of an expressed polypeptide in a biological assay.
- a polypeptide of the invention is expressed in a cell and isolated.
- the expressed polypeptide is tested for an activity in a biological assay and the activity of the expressed polypeptide is identified based on the test results.
- Still another embodiment of the invention provides a substantially pure isolated DNA molecule suitable for use as a probe for genes regulated in atherosclerosis, chosen from the group consisting of the DNA molecules shown in SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ED NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ JD NO:9, SEQ ED NO:10, SEQ ID NO:l l, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ JD NO: 18, SEQ ID NO: 19, SEQ ID NO:20, SEQ ID NO.21, SEQ ED NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ED NO:30, SEQ ID
- kits for detecting the presence of a polypeptide of the invention in a mammalian tissue sample comprises a first antibody which immunoreacts with a mammalian protein encoded by a gene corresponding to the polynucleotide of the invention or with a polypeptide encoded by the polynucleotide in an amount sufficient for at least one assay and suitable packaging material.
- the kit can further comprise a second antibody that binds to the first antibody.
- the second antibody can be labeled with enzymes, radioisotopes, fluorescent compounds, colloidal metals, chemiluminescent compounds, phosphorescent compounds, or bioluminescent compounds.
- Another embodiment of the invention provides a kit for detecting the presence of genes encoding a protein comprising a polynucleotide of the invention, or fragment thereof having at least 10 contiguous bases, in an amount sufficient for at least one assay, and suitable packaging material.
- Yet another embodiment of the invention provides a method for detecting the presence of a nucleic acid encoding a protein in a mammalian tissue sample.
- a polynucleotide of the invention or fragment thereof having at least 10 contiguous bases is hybridized with the nucleic acid of the sample. The presence of the hybridization product is detected.
- Figure 1A-G is a graphical representation of the results of TOGA analysis using a 5' PCR primer with parsing bases AAGC, showing PCR products produced from mRNA extracted from (A) control aorta at day 0 (no cholesterol, no lercanidipine), (B) lercanidipine- treated aorta at day 0 (no cholesterol, 3 mg/kg/week lercanidipine for 2 weeks), (C) control aorta at day 14 of cholesterol administration (1.6g/day cholesterol, no lercanidipine), (D) lercanidipine-treated aorta at day 14 of cholesterol administration (1.6g/day cholesterol, 3 mg/kg/week lercanidipine for 4 weeks), (E) R- lercanidipine treated aorta at day 14 of cholesterol administration (1.6g/day cholesterol, 3 mg/kg/week R-lercanidipine for 4 weeks), (F) control aorta at week 8 of cholesterol administration (1.6g cholesterol
- Figure 2A-C is a graphical representation of more detailed analysis of the 288 b.p. PCR product indicated in Figure 1, using the extended TOGA primer G-A-T-C-G-A-A-T-C-C-G-G- A-A-G-C-C-G-C-A-T-C-A-C-T-G-A-G (SEQ ID NO: 86);
- Figure 3A-G is a graphical representation of the results of TOGA analysis using a 5' PCR primer with parsing bases CACA, showing PCR products produced from mRNA extracted from (A) control aorta at day 0 (no cholesterol, no lercanidipine), (B) lercanidipine- treated aorta at day 0 (no cholesterol, 3 mg/kg/week lercanidipine for 2 weeks), (C) control aorta, at day 14 of cholesterol administration (1.6g/day cholesterol, no lercanidipine), (D) lercani
- Figure 4A-C is a graphical representation of more detailed analysis of the 282 b.p. PCR product indicated in Figure 3, using the extended TOGA primer G-A-T-C-G-A-A-T-C-C-G-G- C-A-C-A-C-G-G-G-C-G-C-A-A-G-A-G-A-G-A (SEQ ID NO: 91).
- Figure 5A-C is a graphical representation of the gene expression profile of the 282 b.p. product indicated in Figure 3 using TOGA analysis (5A-B) and quantitative PCR analysis (5C- D) using RT-PCR primers (SEQ ID NO: 124 and 125).
- Figure 6 is a graphical representation of the results of RT-PCR using 20 pg of clone REC1_1 template, in which amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- G filled squares
- F hypercholesterolemic plus lercanidipine racemate
- Figure 7 is a graphical representation of the results of RT-PCR using 500 pg of clone REC1_2 template, in which amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- G filled squares
- F hypercholesterolemic plus lercanidipine racemate
- Figure 8 is a graphical representation of the results of RT-PCR using 500 pg of clone REC1_3 template, in which amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2"), hypercholesterolemic, (large filled squares, "E”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- E large filled squares
- G hypercholesterolemic
- lercanidipine racemate eight weeks
- Figure 9 is a graphical representation of the results of RT-PCR using 20 pg of clone REC1_8 template, in which amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- G filled squares
- F hypercholesterolemic plus lercanidipine racemate
- Figure 10 is a graphical representation of the results of RT-PCR using 100 pg of clone REC1_10 template, in which amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”) and hypercholesterolemic, (filled squares, "E").
- Figure 11 is a graphical representation of the results of RT-PCR using 20 pg of clone REC1_6 template, in which amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- G filled squares
- F hypercholesterolemic plus lercanidipine racemate
- Figure 12 is a graphical representation of the results of RT-PCR using 100 pg of clone REC1 13 template, in which amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- G filled squares
- F hypercholesterolemic plus lercanidipine racemate
- Figure 13 is a graphical representation of the results of RT-PCR using 20 pg of clone
- REC1_18 template in which amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- Figure 14 is a graphical representation of the results of RT-PCR using 100 pg of clone REC1_7 template, in which amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2"), hypercholesterolemic, hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- hypercholesterolemic hypercholesterolemic
- eight weeks filled squares, "G”
- hypercholesterolemic plus lercanidipine racemate eight weeks
- Figure 15 is a graphical representation of the results of RT-PCR using 100 pg of clone REC1 5 template, in which amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- G filled squares
- F hypercholesterolemic plus lercanidipine racemate
- Figure 16 is a graphical representation of the results of RT-PCR using 20 pg of clone REC1 16 template, in which amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- G filled squares
- F hypercholesterolemic plus lercanidipine racemate
- Figure 17 is a graphical representation of the results of RT-PCR using 20 pg of clone REC1_17 template, in which amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- G filled squares
- F hypercholesterolemic plus lercanidipine racemate
- Figure 18 is a graphical representation of the results of RT-PCR using 100 pg of clone REC1_19 template, in which amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- eight weeks filled squares, "G”
- hypercholesterolemic plus lercanidipine racemate eight weeks
- Figure 19 is a graphical representation of the results of RT-PCR using 20 pg of clone
- REC1_20 template in which amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- Figure 20 is a graphical representation of the results of RT-PCR using 20 pg of clone REC1_21 template, in which amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled squares, "F”).
- Figure 21 is a graphical representation of the results of RT-PCR using 20 pg of clone REC1_12 template, in which amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- G filled squares
- F hypercholesterolemic plus lercanidipine racemate
- Figure 22 is a graphical representation of the results of RT-PCR using 20 pg of clone REC1_22 template, in which amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”) and hypercholesterolemic plus lercanidipine R(-), eight weeks (filled squares, "D”).
- Figure 23 is a graphical representation of the results of RT-PCR using 100 pg of clone RECl 24 template, in which amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”) and hypercholesterolemic plus lercanidipine R(-), eight weeks (filled squares, "D”).
- Figure 24 is a graphical representation of the results of RT-PCR using 100 pg of clone REC1 36 template, in which amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- G filled squares
- F hypercholesterolemic plus lercanidipine racemate
- isolated refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered “by the hand of man” from its natural state.
- an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be “isolated” because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide.
- a "secreted” protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.
- a "polynucleotide” refers to a molecule having a nucleic acid sequence contained in SEQ ID NOs:l-55.
- the polynucleotide can contain all or part of the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence.
- a "polypeptide” refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.
- a “polynucleotide” of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ED NOs: 1-55, or the complement thereof, or the cDNA.
- Stringent hybridization conditions refers to an overnight incubation at 42°C in a solution comprising 50% formamide, 5X SSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5X Denhardt's solution, 10%) dextran sulfate, and 20 mg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in O.lx SSC at about 65°C.
- nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature.
- washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).
- blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations.
- the inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.
- polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide,” since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).
- a polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA.
- polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions.
- a polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA.
- a polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons.
- Modified bases include, for example, tritylated bases and unusual bases such as inosine.
- a variety of modifications can be made to DNA and RNA; thus, "polynucleotide” embraces chemically, enzymatically, or metabolically modified forms.
- the polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids.
- the polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini.
- polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods.
- Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross- linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross r links, formation of cysteine, formation of pyroglutamate, formulation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemizati ⁇ n, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.
- a polypeptide having biological activity refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose- dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about ten-fold less activity and, most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention).
- the translated amino acid sequence beginning with the methionine, is identified although other reading frames can also be easily translated using known molecular biology techniques.
- the polypeptides produced by the translation of these alternative open reading frames are specifically contemplated by the present invention.
- SEQ ID NOs:l-55 and the translations of SEQ ID NOs:l-55 are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. These nucleic acid molecules will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from the translations of SEQ ID NOs:l-55 may be used to generate antibodies which bind specifically to the secreted proteins encoded by the cDNA clones identified.
- DNA sequences generated by sequencing reactions can contain sequencing errors.
- the e ⁇ ors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence.
- the erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence.
- the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9%> identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1,000 bases).
- the present invention also relates to the genes corresponding to SEQ ID NOs:l-55, and translations of SEQ ID NOs:l-55.
- the corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.
- species homologues may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for the desired homologue.
- the polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.
- polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification (such as multiple histidine residues), or an additional sequence for stability during recombinant production.
- polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified.
- a recombinantly produced version of a polypeptide, including the secreted polypeptide can be substantially purified by the one-step method described in Smith & Johnson, Gene, 67:31-40 (1988).
- Polypeptides of the invention also can be purified from natural or recombinant sources using antibodies of the invention raised against the secreted protein in methods which are well known in the art.
- the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called Signal P (Nielsen et al., Protein Engineering, 10:1-6 (1997), which predicts the cellular location of a protein based on the amino acid sequence.
- Signal P Neelsen et al., Protein Engineering, 10:1-6 (1997), which predicts the cellular location of a protein based on the amino acid sequence.
- McGeoch and von Heinje are incorporated.
- the present invention provides secreted polypeptides having a sequence corresponding to the translations of SEQ ID NOs:l-55 which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point.
- secreted polypeptides having a sequence corresponding to the translations of SEQ ID NOs:l-55 which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point.
- cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species.
- the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence.
- the naturally occurring signal sequence may be further upstream from the predicted signal sequence.
- the predicted signal sequence will be capable of directing the secreted protein to the ER.
- Variant refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. In general, variants have close similarity overall and are identical in many regions to the polynucleotide or polypeptide of the present invention.
- identity is well known to skilled artisans (Carillo et al., SIAM J Applied Math., 48:1073 (1988)). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in "Guide to Huge Computers,” Martin J. Bishop, Ed., Academic Press, San Diego, (1994) and Carillo et al., (1988), Supra. Methods for aligning polynucleotides or polypeptides are codified in computer programs, including the GCG program package (Devereux et al., Nuc. Acids Res.
- the parameters are set such that the percentage of identity is calculated over the full length of the reference polynucleotide and that gaps in identity of up to 5% of the total number of nucleotides in the reference polynucleotide are allowed.
- a preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci., 6:237-245 (1990)).
- sequence includes nucleotide and amino acid sequences.
- the query and subject sequences are either both nucleotide sequences or both amino acid sequences.
- the result of said global sequence alignment is presented in terms of percent identity. Preferred parameters used in a FASTDB search of a DNA sequence to calculate percent identity are:
- a polynucleotide having a nucleotide sequence of at least 95% "identity" to a sequence contained in SEQ ED NOs:l-55 means that the polynucleotide is identical to a sequence contained in SEQ ID NOs:l-55 or the cDNA except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the total length (not just within a given 100 nucleotide stretch).
- nucleotide sequence at least 95% identical to SEQ ID NOs:l-55
- up to 5% of the nucleotides in the sequence contained in SEQ ID NOs:l-55 or the cDNA can be deleted, inserted, or substituted with other nucleotides. These changes may occur anywhere throughout the polynucleotide.
- polynucleotides having at least 85%, 90%, 95%, 96%, 97%, 98%, or 99%> identity will encode a polypeptide identical to an amino acid sequence contained in the translations of SEQ ID NOs:l-55.
- a polypeptide having an amino acid sequence having at least, for example, 95%o "identity" to a reference polypeptide is intended that the amino acid sequence of the polypeptide is identical to the reference polypeptide except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the total length of the reference polypeptide.
- the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the total length of the reference polypeptide.
- up to 5%> of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5%> of the total amino acid residues in the reference sequence may be inserted into the reference sequence.
- These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.
- the above polypeptides should exhibit at least one biological activity of the protein.
- polypeptides of the present invention include polypeptides having at least 90%> similarity, more preferably at least 95%> similarity, and still more preferably at least 96%>, 97%o, 98%o, or 99%> similarity to an amino acid sequence contained in translations of SEQ ID NOs: l-55.
- the variants may contain alterations in the coding regions, non-coding regions, or both.
- polynucleotide variants containing alterations that produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide.
- Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are prefe ⁇ ed.
- variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also prefe ⁇ ed.
- Polynucleotide variants can be produced for a variety of reasons.
- a polynucleotide variant may be produced to optimize codon expression for a particular host (i.e., codons in the human mRNA may be changed to those prefe ⁇ ed by a bacterial host, such as E. coli).
- Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism (Lewin, Ed., Genes II, John Wiley & Sons, New York (1985)). These allelic variants can vary at either the polynucleotide and/or polypeptide level. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.
- variants may be generated to improve or alter the characteristics of the polypeptides of the present invention.
- one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function.
- Ron et al. reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues (J. Biol. Chem. 268: 2984-2988 (1993)).
- interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein (Dobeli et al., J. Biotechnology, 7:199-216 (1988)).
- the invention further includes polypeptide variants which show substantial biological activity.
- variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity.
- guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., Science, 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.
- the first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, the amino acid positions which have been conserved between species can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions in which substitutions have been tolerated by natural selection indicate positions which are not critical for protein function. Thus, positions tolerating amino acid substitution may be modified while still maintaining biological activity of the protein.
- the second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site-directed mutagenesis or alanine-scanning mutagenesis (the introduction of single alanine mutations at every residue in the molecule) can be used (Cunningham et al., Science, 244:1081-1085 (1989)). The resulting mutant molecules can then be tested for biological activity.
- tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and He; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gin; replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Tip; and replacement of the small- sized amino acids Ala, Ser, Thr, Met, and Gly.
- variants of the present invention include: (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code; (ii) substitution with one or more of amino acid residues having a substituent group; (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (e.g., polyethylene glycol); (iv) fusion of the polypeptide with additional amino acids, such as an IgG Fc fusion region peptide, a leader or secretory sequence, or a sequence facilitating purification.
- substitutions with one or more of the non-conserved amino acid residues where the substituted amino acid residues may or may not be one encoded by the genetic code
- substitution with one or more of amino acid residues having a substituent group such as a compound to increase the stability and/or solubility of the polypeptide (e.g., poly
- polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as decreased aggregation.
- aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity (see, e.g., Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes, 36: 838-845 (1987); Cleland et al., Crit. Rev. Therap. Drug Carrier Sys., 10:307-377 (1993)).
- a "polynucleotide fragment” refers to a short polynucleotide having a nucleic acid sequence contained in that shown in SEQ ID NOs: 1-55.
- the short nucleotide fragments are preferably at least about 15 nucleotides (nt), and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length.
- a fragment "at least 20 nt in length,” for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in that shown in SEQ ID NOs: 1-55.
- These nucleotide fragments are useful as diagnostic probes and primers as discussed herein.
- larger fragments e.g., 50, 150, and greater than 150 nucleotides are prefe ⁇ ed.
- polynucleotide fragments of the invention include, for example, fragments having a sequence from about nucleotide number 1-50, 51- 100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, to the end of SEQ ID NOs: 1 -55.
- “about” includes the particularly recited ranges, larger or smaller by several nucleotides (i.e., 5, 4, 3, 2, or 1 nt) at either terminus or at both termini.
- these fragments encode a polypeptide which has biological activity.
- polypeptide fragment refers to a short amino acid sequence contained in the translations of SEQ ID NOs: 1-55. Protein fragments may be "free-standing,” or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention include, for example, fragments from about amino acid number 1-20, 21-40, 41- 60, or 61 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, or 60 amino acids in length. In this context "about” includes the particularly recited ranges, larger or smaller by several amino acids (5, 4, 3, 2, or 1) at either extreme or at both extremes.
- Prefe ⁇ ed polypeptide fragments include the secreted protein as well as the mature form. Further prefe ⁇ ed polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are prefe ⁇ ed. Similarly, polynucleotide fragments encoding these polypeptide fragments are also prefe ⁇ ed.
- polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix- forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions.
- Polypeptide fragments of the translations of SEQ ID NOs: 1-55 falling within conserved domains are specifically contemplated by the present invention.
- polynucleotide fragments encoding these domains are also contemplated.
- Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention.
- the biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.
- epitopes refer to polypeptide fragments having antigenic or immunogenic activity in an animal, especially in a human.
- a prefe ⁇ ed embodiment of the present invention relates to a polypeptide fragment comprising an epitope, as well as the polynucleotide encoding this fragment.
- a region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope.”
- an "immunogenic epitope” is defined as a part of a protein that elicits an antibody response. (See, e.g., Geysen et al., Proc. Natl. Acad. Sci. USA, 81 :3998-4002 (1983)).
- Fragments which function as epitopes may be produced by any conventional means.
- antigenic epitopes preferably contain a sequence of at least seven, more preferably at least nine, and most preferably between about 15 to about 30 amino acids.
- Antigenic epitopes are useful to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. (See, e.g., Wilson et al., Cell, 37:767-778 (1984); Sutcliffe et al, Science, 219:660-666 (1983)).
- immunogenic epitopes can be used to induce antibodies according to methods well known in the art. (See, e.g., Sutcliffe et al., (1983) Supra; Wilson et al., (1984) Supra; Chow et al., Proc Natl. Acad. Sci., USA, 82:910-914; and Bittle et al., J Gen. Virol, 66:2347-2354 (1985)).
- a prefe ⁇ ed immunogenic epitope includes the secreted protein.
- the immunogenic epitope may be presented together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse).
- the immunogenic epitope may be prescribed without a ca ⁇ ier, if the sequence is of sufficient length (at least about 25 amino acids).
- immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting.)
- antibody As used herein, the term "antibody” (Ab) or “monoclonal antibody” (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab') 2 fragments) which are capable of specifically binding to protein. Fab and F(ab') 2 fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody (Wahl et al., J. Nucl Med., 24:316-325 (1983)). Thus, these fragments are prefe ⁇ ed, as well as the products of a Fab or other immunoglobulin expression library. Moreover, antibodies of the present invention include chimeric, single chain, and human and humanized antibodies.
- chimeric antibodies e.g., humanized versions of murine monoclonal antibodies.
- Such humanized antibodies may be prepared by known techniques, and offer the advantage of reduced immunogenicity when the antibodies are administered to humans.
- a humanized monoclonal antibody comprises the variable region of a murine antibody (or just the antigen binding site thereof) and a constant region derived from a human antibody.
- a humanized antibody fragment may comprise the antigen binding site of a murine monoclonal antibody and a variable region fragment (lacking the antigen-binding site) derived from a human antibody.
- Procedures for the production of chimeric and further engineered monoclonal antibodies include those described in Riechmann et al.
- One method for producing a human antibody comprises immunizing a non-human animal, such as a transgenic mouse, with a polypeptide translated from a nucleotide sequence chosen from SEQ ID NOs: 1-55, whereby antibodies directed against the polypeptide translated from a nucleotide sequence chosen from SEQ ED NOs: 1-55 are generated in said animal.
- Procedures have been developed for generating human antibodies in non-human animals.
- the antibodies may be partially human, or preferably completely human.
- Non-human animals (such as transgenic mice) into which genetic material encoding one or more human immunoglobulin chains has been introduced may be employed. Such transgenic mice may be genetically altered in a variety of ways.
- the genetic manipulation may result in human immunoglobulin polypeptide chains replacing endogenous immunoglobulin chains in at least some (preferably virtually all) antibodies produced by the animal upon immunization.
- Antibodies produced by immunizing transgenic animals with a polypeptide translated from a nucleotide sequence chosen from SEQ ID NOs: 1-55 are provided herein. Mice in which one or more endogenous immunoglobulin genes are inactivated by various means have been prepared. Human immunoglobulin genes have been introduced into the mice to replace the inactivated mouse genes.
- Antibodies produced in the animals incorporate human immunoglobulin polypeptide chains encoded by the human genetic material introduced into the animal. Examples of techniques for production and use of such transgenic animals are described in U.S. Patent Nos.5,814,318, 5,569,825, and 5,545,806, which are incorporated by reference herein.
- Monoclonal antibodies may be produced by conventional procedures, e.g., by immortalizing spleen cells harvested from the transgenic animal after completion of the immunization schedule.
- the spleen cells may be fused with myeloma cells to produce hybridomas by conventional procedures.
- a method for producing a hybridoma cell line comprises immunizing such a transgenic animal with an immunogen comprising at least seven contiguous amino acid residues of a polypeptide translated from a nucleotide sequence chosen from SEQ ID NOs: 1-55; harvesting spleen cells from the immunized animal; fusing the harvested spleen cells to a myeloma cell line, thereby generating hybridoma cells; and identifying a hybridoma cell line that produces a monoclonal antibody that binds a polypeptide translated from a nucleotide sequence chosen from SEQ ID NOs: 1-55.
- Such hybridoma cell lines, and monoclonal antibodies produced therefrom, are encompassed by the present invention.
- Monoclonal antibodies secreted by the hybridoma cell line are purified by conventional techniques.
- Antibodies may be employed in an in vitro procedure, or administered in vivo to inhibit biological activity induced by a polypeptide translated from a nucleotide sequence chosen from SEQ ED NOs:l-55. Disorders caused or exacerbated (directly or indirectly) by the interaction of such polypeptides of the present invention with cell surface receptors thus may be treated.
- a therapeutic method involves in vivo administration of a blocking antibody to a mammal in an amount effective for reducing a biological activity induced by a polypeptide translated from a nucleotide sequence chosen from SEQ ED NOs: 1-55.
- antibody blockade of the LDL lipoproteins to receptors at sites of endothelium injury may inhibit the formation of atherosclerotic plaques.
- antibody blockade of macrophage or platelet adhesion to endothelial lesions may block the initiation of plaque formation.
- conjugates comprising a detectable (e.g., diagnostic) or therapeutic agent, attached to an antibody directed against a polypeptide translated from a nucleotide sequence chosen from SEQ ED NOs: 1-55.
- detectable or therapeutic agent attached to an antibody directed against a polypeptide translated from a nucleotide sequence chosen from SEQ ED NOs: 1-55.
- agents are well known, and include but are not limited to diagnostic radionuclides, therapeutic radionuclides, and cytotoxic drugs.
- the conjugates find use in in vitro or in vivo procedures.
- any polypeptide of the present invention can be used to generate fusion proteins.
- the polypeptide of the present invention when fused to a second protein, can be used as an antigenic tag.
- Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide.
- secreted proteins target cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.
- domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions.
- the fusion does not necessarily need to be direct, but may occur through linker sequences.
- fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.
- polypeptides of the present invention can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides.
- IgG immunoglobulins
- EP A 0 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof.
- the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties (see, e.g., EP A 0 232 262).
- deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired.
- the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations.
- human proteins such as hIL-5
- Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5 (See, Bennett et al., J Mol. Recognition 8:52-58 (1995); Johanson et al., J. Biol Chem., 270:9459-9471 (1995)).
- the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide.
- the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., Chatsworth, CA), among others, many of which are commercially available.
- hexa-histidine provides for convenient purification of the fusion protein (Proc. Natl. Acad. Sci. USA 86:821-824 (1989)).
- HA hemagglutinin protein
- Other fusion proteins may use the ability of the polypeptides of the present invention to target the delivery of a biologically active peptide. This might include focused delivery of a toxin to tumor cells, or a growth factor to stem cells.
- any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.
- Vectors, Host Cells, and Protein Production are engineered using the polynucleotides or the polypeptides of the present invention.
- the present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques.
- the vector may be, for example, a phage, plasmid, viral, or retroviral vector.
- Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.
- the polynucleotides may be joined to a vector containing a selectable marker for propagation in a host.
- a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.
- the polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan.
- the expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation.
- the coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.
- the expression vectors will preferably include at least one selectable marker.
- markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria.
- Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells, and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.
- vectors prefe ⁇ ed for use in bacteria include pQ ⁇ 70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, PNH16A, PNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc.
- prefe ⁇ ed eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXTl and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia.
- Other suitable vectors will be readily apparent to the skilled artisan.
- Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may, in fact, be expressed by a host cell lacking a recombinant vector.
- a polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods, including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, and lectin chromatography. Most preferably, high performance liquid chromatography (“HPLC”) is employed for purification.
- HPLC high performance liquid chromatography
- Polypeptides of the present invention can also be recovered from products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells.
- a prokaryotic or eukaryotic host including, for example, bacterial, yeast, higher plant, insect, and mammalian cells.
- the polypeptides of the present invention may be glycosylated or may be non-glycosylated.
- polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes.
- N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N- terminal methionine is covalently linked.
- the polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents based on actual sequence data (repeat polymorphisms) are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.
- sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NOs: 1-55. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene co ⁇ esponding to the SEQ ED NOs: 1-55 will yield an amplified fragment.
- somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments.
- Other gene-mapping strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.
- Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread.
- FISH fluorescence in situ hybridization
- This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides of 2,000-4,000 bp are prefe ⁇ ed.
- Verma et al. Human Chromosomes: a Manual of Basic Techniques, Pergamon Press, New York (1988).
- the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes).
- Prefe ⁇ ed polynucleotides co ⁇ espond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross-hybridization during chromosomal mapping.
- Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease.
- Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library)). Assuming one megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.
- polynucleotide and the co ⁇ esponding gene between affected and unaffected individuals can be examined.
- the polynucleotides of SEQ ID NOs: 1-55 can be used for this analysis of individuals.
- Some genes may be associated with susceptibility to atherosclerosis. These may be indirect, through associations with risk factors such as diabetes, or direct, through genetic defects in lipid or cholesterol metabolism. These can be used as markers to identify individuals with susceptibility to atherosclerosis.
- a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Both methods rely on binding of the polynucleotide to DNA or RNA. For these techniques, prefe ⁇ ed polynucleotides are usually 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (see, Lee et al., Nucl.
- Polynucleotides of the present invention are also useful in gene therapy.
- One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to co ⁇ ect the genetic defect.
- the polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner.
- Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.
- the polynucleotides are also useful for identifying individuals from minute biological samples.
- the United States military for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel.
- RFLP restriction fragment length polymorphism
- an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel.
- This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult.
- the polynucleotides of the present invention can be used as additional DNA markers for RFLP.
- the polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.
- DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, etc.
- DNA sequences amplified from polymo ⁇ hic loci such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, Ed., PCR Technology, M. Stockton Press (1989)).
- polymo ⁇ hic loci are amplified, they are digested with one or more restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA co ⁇ esponding to the DQa class H HLA gene.
- polynucleotides of the present invention can be used as polymo ⁇ hic markers for forensic pu ⁇ oses.
- reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin.
- Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.
- the polynucleotides of the present invention can be used as molecular weight markers on Southern gels; as diagnostic probes for the presence of a specific mRNA in a particular cell type; as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip” or other support; to raise anti-DNA antibodies using DNA immunization techniques; and as an antigen to elicit an immune response.
- a polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques.
- protein expression in tissues can be studied with classical immunohistological methods (Jalkanen, et al, J. Cell. Biol,
- antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA).
- ELISA enzyme linked immunosorbent assay
- RIA radioimmunoassay
- Suitable antibody assay labels include enzyme labels, such as glucose oxidase; and radioisotopes, such as iodine ( 125 1, 121 I), carbon ( 14 C), sulfur ( 35 S), tritium ( 3 H), indium ( 112 In), and technetium ( 99m Tc); fluorescent labels, such as fluorescein and rhodamine; and biotin.
- proteins can also be detected in vivo by imaging.
- Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, nuclear magnetic resonance (NMR), or ESR.
- suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject.
- suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be inco ⁇ orated into the antibody by labeling of nutrients for the relevant hybridoma.
- a protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety such as a radioisotope (e.g., 131 I, H2 In, 99m Tc), a radio-opaque substance, or a material detectable by NMR, is introduced (e.g., parenterally, subcutaneously, or intraperitoneally) into the mammal.
- a radioisotope e.g., 131 I, H2 In, 99m Tc
- a radio-opaque substance e.g., a radio-opaque substance, or a material detectable by NMR
- the labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein.
- In vivo tumor imaging is described in Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments” (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, Burchiel and Rhodes, Eds., Masson Publishing Inc. (1982)).
- the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual, and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder.
- a diagnostic method of a disorder which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual, and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder.
- macrophages activated in atherosclerotic lesions may show specific changes in gene expression. If these changes are also found in macrophages circulating in peripheral blood, this may be detected in blood samples from patients.
- polypeptides of the present invention can be used to treat disease.
- patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin); to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B); to inhibit the activity of a polypeptide (e.g., an oncogene); to activate the activity of a polypeptide (e.g., by binding to a receptor); to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation); or to bring about a desired response (e.g., blood vessel growth).
- a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin); to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B); to inhibit the activity of a polypeptide (
- antibodies directed to a polypeptide of the present invention can also be used to treat disease.
- administration of an antibody directed to a polypeptide of the present invention can bind and reduce ove ⁇ roduction of the polypeptide.
- administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).
- Polypeptides can be used as antigens to trigger immune responses.
- activated macrophages that are filled with lipid in atherosclerotic lesions may express genes unique to this activated state. Immunization against these markers may stimulate antibody responses or cellular immune responses that could eliminate the lipid- laden macrophages, and eliminate the atherosclerotic lesions.
- polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well-known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.
- polynucleotides and polypeptides of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides and polypeptides could be used to treat the associated disease.
- a polypeptide or polynucleotide of the present invention may be useful in treating deficiencies or disorders of the central nervous system or peripheral nervous system by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of neuroblasts, stem cells, or glial cells. Also, a polypeptide or polynucleotide of the present invention may be useful in treating deficiencies or disorders of the central nervous system or peripheral nervous system by activating or inhibiting the mechanisms of synaptic transmission, synthesis, metabolism and inactivation of neural transmitters, neuromodulators and trophic factors, and by activating or inhibiting the expression and inco ⁇ oration of enzymes, structural proteins, membrane channels, and receptors in neurons and glial cells.
- the etiology of these deficiencies or disorders may be genetic, somatic (such as cancer or some autoimmune disorder), acquired (e.g., by chemotherapy or toxins), or infectious.
- a polynucleotide or polypeptide of the present invention can be used as a marker or detector of a particular nervous system disease or disorder.
- the disorder or disease can be any of Alzheimer's disease, Pick's disease, Binswanger's disease, other senile dementia, Parkinson's disease, parkinsonism, obsessive compulsive disorders, epilepsy, encephaolopathy, ischemia, alcohol addiction, drug addiction, schizophrenia, amyotrophic lateral sclerosis, multiple sclerosis, depression, and bipolar manic-depressive disorder.
- the polypeptide or polynucleotide of the present invention can be used to study circadian variation, aging, or long-term potentiation, the latter affecting the hippocampus. Additionally, particularly with reference to mRNA species occu ⁇ ing in particular structures within the central nervous system, the polypeptide or polynucleotide of the present invention can be used to study brain regions that are known to be involved in complex behaviors, such as learning and memory, emotion, drug addiction, glutamate neurotoxicity, feeding behavior, olfaction, viral infection, vision, and movement disorders.
- a polypeptide or polynucleotide of the present invention may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells.
- Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells.
- the etiology of these immune deficiencies or disorders may be genetic, somatic (such as cancer or some autoimmune disorders) acquired (e.g., by chemotherapy or toxins), or infectious.
- a polynucleotide or polypeptide of the present invention can be used as a marker or detector of a particular immune system disease or disorder.
- a polynucleotide or polypeptide of the present invention may be useful in treating or detecting deficiencies or disorders of hematopoietic cells.
- a polypeptide or polynucleotide of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat those disorders associated with a decrease in certain (or many) types hematopoietic cells.
- immunologic deficiency syndromes include, but are not limited to: blood protein disorders (e.g.
- agammaglobulinemia dysgammaglobulinemia
- ataxia telangiectasia common variable immunodeficiency
- Di George's Syndrome HIV infection
- HTLV-BLV infection leukocyte adhesion deficiency syndrome
- lymphopenia phagocyte bactericidal dysfunction
- severe combined immunodeficiency SCIDs
- Wiskott-Aldrich Disorder anemia, thrombocytopenia, or hemoglobinuria.
- a polypeptide or polynucleotide of the present invention could also be used to modulate hemostatic (bleeding cessation) or thrombolytic activity (clot formation).
- a polynucleotide or polypeptide of the present invention could be used to treat blood coagulation disorders (e.g., afibrinogenemia, factor deficiencies), blood platelet disorders (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes.
- blood coagulation disorders e.g., afibrinogenemia, factor deficiencies
- blood platelet disorders e.g. thrombocytopenia
- wounds resulting from trauma, surgery, or other causes e.g., a polynucleotide or polypeptide of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment of heart attacks (infarction), strokes, or scarring.
- a polynucleotide or polypeptide of the present invention may also be useful in the treatment or detection of autoimmune disorders.
- Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T- cells response or in some way results in the induction of tolerance, may be an effective therapy in preventing autoimmune disorders.
- autoimmune disorders examples include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Pu ⁇ ura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Ba ⁇ e Syndrome, insulin dependent diabetes mellitis, and autoimmune inflammatory eye disease.
- a polypeptide or polynucleotide of the present invention may also be treated by a polypeptide or polynucleotide of the present invention.
- these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.
- a polynucleotide or polypeptide of the present invention may also be used to treat and/or prevent organ rejection or graft-versus-host disease (GVHD).
- Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response.
- an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues.
- the administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells may be an effective therapy in preventing organ rejection or GVHD.
- a polypeptide or polynucleotide of the present invention may also be used to modulate inflammation.
- the polypeptide or polynucleotide may inhibit the proliferation and differentiation of cells involved in an inflammatory response.
- These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)
- SIRS systemic inflammatory response syndrome
- a polypeptide or polynucleotide can be used to treat or detect hype ⁇ roliferative disorders, including neoplasms.
- a polypeptide or polynucleotide of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions.
- a polypeptide or polynucleotide of the present invention may proliferate other cells which can inhibit the hype ⁇ roliferative disorder.
- hype ⁇ roliferative disorders can be treated.
- This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response.
- decreasing an immune response may also be a method of treating hype ⁇ roliferative disorders, such as by administering the polypeptide or polynucleotide as a chemotherapeutic agent.
- Examples of hype ⁇ roliferative disorders that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but are not limited to neoplasms located in the abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous system (central and peripheral), lymphatic system, pelvic region, skin, soft tissue, spleen, thoracic region, and urogenital system.
- neoplasms located in the abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous system (central and peripheral), lymphatic system, pelvic region, skin, soft tissue, spleen, thoracic region
- hype ⁇ roliferative disorders can also be treated or detected by a polynucleotide or polypeptide of the present invention.
- hype ⁇ roliferative disorders include, but are not limited to hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, pu ⁇ ura, sarcoidosis, Sezary Syndrome, Waldenstron's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hype ⁇ roliferative disease, besides neoplasia, located in an organ system listed above.
- a polypeptide or polynucleotide of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated.
- the immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response.
- the polypeptide or polynucleotide of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.
- viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention.
- viruses include, but are not limited to, the following DNA and RNA viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Flaviviridae, Hepadnaviridae (Hepatitis), He ⁇ esviridae (such as Cytomegalovirus, He ⁇ es Simplex, He ⁇ es Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza), Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or
- Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to, arthritis, bronchiollitis, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemo ⁇ hagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia.
- a polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.
- bacteremia e.g., endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections (such as whooping Cough or empyema), sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gono ⁇ hea, meningitis, Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually-transmitted diseases, skin diseases (e.g., cell
- parasitic agents causing disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but are not limited to, the following families: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomoniasis.
- These parasites can cause a variety of diseases or symptoms, including, but not limited to, Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), Malaria, pregnancy complications, and toxoplasmosis.
- a polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.
- treatment using a polypeptide or polynucleotide of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy).
- the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.
- a polynucleotide or polypeptide of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues (see, Science, 276:59-87 (1997)).
- the regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteocarthritis, periodontal disease, liver failure), surgery (including cosmetic plastic surgery), fibrosis, reperfusion injury, or systemic cytokine damage.
- Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vascular (including vascular endothelium), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, ligament) tissue.
- organs e.g., pancreas, liver, intestine, kidney, skin, endothelium
- muscle smooth, skeletal or cardiac
- vascular including vascular endothelium
- nervous hematopoietic
- skeletal bone, cartilage, tendon, ligament
- Regeneration also may include angiogenesis.
- atherosclerosis improper healing of vascular endothelium lesions may be the primary trigger of atherosclerotic plaque formation. Molecules that may induce more efficient wound healing may prevent plaque formation.
- a polynucleotide or polypeptide of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage.
- a polynucleotide or polypeptide of the present invention could also be used prophylactically in an effort to avoid damage.
- Specific diseases that could be treated include of tendinitis, ca ⁇ al tunnel syndrome, and other tendon or ligament defects.
- tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.
- nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide of the present invention to proliferate and differentiate nerve cells.
- Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke).
- diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome
- Alzheimer's disease Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome
- a polynucleotide or polypeptide of the present invention may have chemotaxis activity.
- a chemotaxic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T- cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hype ⁇ roliferation.
- the mobilized cells can then fight off and/or heal the particular trauma or abnormality.
- a polynucleotide or polypeptide of the present invention may increase chemotaxic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hype ⁇ roliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotaxic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds. It is also contemplated that a polynucleotide or polypeptide of the present invention may inhibit chemotactic activity. Such molecules could also be used to treat a variety of disorders.
- a polynucleotide or polypeptide of the present invention could be used as an inhibitor of chemotaxis.
- the initial recruitament and activation of macrophages to vascular endothelium lesions may depend on chemotactic signals. Blockade of this step may prevent development of atherosclerotic plaques.
- Atherosclerotic plaque develops over several decades and involves inflammatory cell infiltration, smooth muscle cell proliferation, accumulation of extracellular matrix, fibrous cap formation, and angiogenesis.
- Chemotaxis is involved in the early development of atherosclerosis. Cell populations migrate toward the inner part of the vascular wall and originate the neointima, which leads to the formation of an atherosclerotic plaque. For example, monocyte chemotaxis is induced by monocyte chemoattractant protein 1 (MCP-1), which is expressed early in the development of atherosclerosis in the injured arterial wall.
- MCP-1 monocyte chemoattractant protein 1
- IGF insulin-like growth factors
- vascular endothelial growth factor has been shown to be a critical regulator of angiogenesis that stimulates proliferation, migration and proteolytic activity of endothelial cells.
- VEGF vascular endothelial growth factor
- VEGF is able to stimulate chemotaxis in monocytes and can enhance matrix metalloproteinase expression and accelerate smooth muscle cell migration.
- Blockade of one or more of these chemotaxic activities may prevent development of atherosclerotic plaques.
- a polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds.
- the binding of the polypeptide and the molecule may activate (i.e., an agonist), increase, inhibit (i.e., an antagonist), or decrease activity of the polypeptide or the molecule bound.
- Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.
- the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic (see, Coligan et al., Current Protocols in Immunology 1(2), Chapter 5 (1991)).
- the molecule can be closely related to the natural receptor to which the polypeptide binds or, at least, related to a fragment of the receptor capable of being bound by the polypeptide (e.g., an active site). In either case, the molecule can be rationally designed using known techniques.
- the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane.
- Prefe ⁇ ed cells include cells from mammals, yeast, Drosophila, or E. coli.
- Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.
- the assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.
- the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures.
- the assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.
- an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody.
- the antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate. All of these above assays can be used as diagnostic or prognostic markers.
- the molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule.
- the assays can discover agents which may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues.
- Atherosclerosis e.g., hyper- lipidemia
- New assays using markers generated from materials of the present invention may provide some specific indicators of active disease.
- the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a candidate binding compound with a polypeptide of the invention; and (b) determining if binding has occu ⁇ ed.
- the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the invention, (b) assaying a biological activity, and (c) determining if a biological activity of the polypeptide has been altered.
- a polypeptide or polynucleotide of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells from a lineage other than the above- described hemopoietic lineage.
- a polypeptide or polynucleotide of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery).
- a polypeptide or polynucleotide of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.
- a polypeptide or polynucleotide of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, circadian rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, the response to opiates and opioids, tolerance to opiates and opioids, withdrawal from opiates and opioids, reproductive capabilities (preferably by activin or inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.
- a polypeptide or polynucleotide of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors, or other nutritional components.
- a polynucleotide of the invention is down-regulated and exacerbates a pathological condition, such as atherosclerosis
- the expression of the polynucleotide can be increased or the level of the intact polypeptide product can be increased in order to treat, prevent, ameliorate, or modulate the pathological condition. This can be accomplished by, for example, administering a polynucleotide or polypeptide of the invention to the mammalian subject.
- a polynucleotide of the invention can be administered to a mammalian subject by a recombinant expression vector comprising the polynucleotide.
- a mammalian subject can be a human, baboon, chimpanzee, macaque, cow, horse, sheep, pig, horse, dog, cat, rabbit, guinea pig, rat or mouse.
- the recombinant vector comprises a polynucleotide shown in SEQ ID NOs: 1-55 or a polynucleotide which is at least 98%> identical to a nucleic acid sequence shown in SEQ ID NOs: 1-55.
- the recombinant vector comprises a variant polynucleotide that is at least 80%>, 90%>, or 95%> identical to a polynucleotide comprising SEQ ID NOs:l-55.
- a polynucleotide or recombinant expression vector of the invention can be used to express a polynucleotide in said subject for the treatment of, for example, atherosclerosis.
- Expression of a polynucleotide in target cells, including but not limited to atherosclerosis cells, would effect greater production of the encoded polypeptide.
- the regulation of other genes may be secondarily up- or down-regulated.
- a naked polynucleotide can be administered to target cells.
- Polynucleotides and recombinant expression vectors of the invention can be administered as a pharmaceutical composition.
- Such a composition comprises an effective amount of a polynucleotide or recombinant expression vector, and a pharmaceutically acceptable formulation agent selected for suitability with the mode of administration.
- Suitable formulation materials preferably are non-toxic to recipients at the concentrations employed and can modify, maintain, or preserve, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adso ⁇ tion, or penetration of the composition. See Remington 's Pharmaceutical Sciences (18 th Ed., A.R. Gennaro, ed., Mack Publishing Company 1990).
- the pharmaceutically active compounds i.e., a polynucleotide or a vector
- the pharmaceutical composition comprising a polynucleotide or a recombinant expression vector may be made up in a solid form (including granules, powders or suppositories) or in a liquid form (e.g. , solutions, suspensions, or emulsions).
- the dosage regimen for treating a disease with a composition comprising a polynucleotide or expression vector is based on a variety of factors, including the type or severity of the atherosclerosis, the age, weight, sex, medical condition of the patient, the route of administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined routinely using standard methods. A typical dosage may range from about 0.1 mg/kg to about 100 mg/kg or more, depending on the factors mentioned above.
- the frequency of dosing will depend upon the pharmacokinetic parameters of the polynucleotide or vector in the formulation being used. Typically, a clinician will administer the composition until a dosage is reached that achieves the desired effect.
- the composition may therefore be administered as a single dose, as two or more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via implantation device or catheter. Further refinement of the appropriate dosage is routinely made by those of ordinary skill in the art and is within the ambit of tasks routinely performed by them. Appropriate dosages may be ascertained through use of appropriate dose-response data.
- the cells of a mammalian subject may be transfected in vivo, ex vivo, or in vitro.
- Administration of a polynucleotide or a recombinant vector containing a polynucleotide to a target cell in vivo may be accomplished using any of a variety of techniques well known to those skilled in the art.
- U.S. Patent No. 5,672,344 describes an in vivo viral- mediated gene transfer system involving a recombinant neurotrophic HSV-1 vector.
- compositions of polynucleotides and recombinant vectors can be transfected in vivo by oral, buccal, parenteral, rectal, or topical administration as well as by inhalation spray.
- parenteral as used herein includes, subcutaneous, intravenous, intramuscular, intrasternal, infusion techniques or intraperitoneally.
- nucleic acids and/or vectors of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more vectors of the invention or other agents.
- the therapeutic agents can be formulated as separate compositions that are given at the same time or different times, or the therapeutic agents can be given as a single composition.
- Non-viral delivery system Another delivery system for polynucleotides of the invention is a "non-viral" delivery system.
- Techniques that have been used or proposed for gene therapy include DNA-ligand complexes, adenovirus-ligand-DNA complexes, direct injection of DNA, CaPO 4 precipitation, gene gun techniques, electroporation, lipofection, and colloidal dispersion (Mulligan, R., (1993) Science, 260 (5110):926-32). Any of these methods are widely available to one skilled in the art and would be suitable for use in the present invention. Other suitable methods are available to one skilled in the art, and it is to be understood that the present invention may be accomplished using any of the available methods of transfection. Several such methodologies have been utilized by those skilled in the art with varying success (Mulligan, R., (1993) Science, 260 (5110):926-32).
- a polynucleotide of the invention is up-regulated and exacerbates a pathological condition in a mammalian subject, such as atherosclerosis
- the expression of the polynucleotide can be blocked or reduced or the level of the intact polypeptide product can be reduced in order to treat, prevent, ameliorate, or modulate the pathological condition.
- This can be accomplished by, for example, the use of antisense oligonucleotides or ribozymes.
- drugs or antibodies that bind to and inactivate the polypeptide product can be used.
- Antisense oligonucleotides are nucleotide sequences which are complementary to a specific DNA or RNA sequence. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form complexes and block either transcription or translation. Preferably, an antisense oligonucleotide is at least 11 nucleotides in length, but can be at least 12, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides long. Longer sequences also can be used. Antisense oligonucleotide molecules can be provided in a DNA construct and introduced into a cell as described above to decrease the level of gene products of the invention in the cell.
- Antisense oligonucleotides can be deoxyribonucleotides, ribonucleotides, or a combination of both. Oligonucleotides can be synthesized manually or by an automated synthesizer, by covalently linking the 5' end of one nucleotide with the 3' end of another nucleotide with non-phosphodiester internucleotide linkages such alkylphosphonates, phosphorothioates, phosphorodithioates, alkylphosphonothioates, alkylphosphonates, phosphoramidates, phosphate esters, carbamates, acetamidate, carboxymethyl esters, carbonates, and phosphate triesters.
- Modifications of gene expression can be obtained by designing antisense oligonucleotides which will form duplexes to the control, 5', or regulatory regions of a gene of the invention. Oligonucleotides derived from the transcription initiation site, e.g., between positions -10 and +10 from the start site, are prefe ⁇ ed. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or chaperons.
- An antisense oligonucleotide also can be designed to block translation of mRNA by preventing the transcript from binding to ribosomes. Precise complementarity is not required for successful complex formation between an antisense oligonucleotide and the complementary sequence of a polynucleotide.
- Antisense oligonucleotides which comprise, for example, 2, 3, 4, or 5 or more stretches of contiguous nucleotides which are precisely complementary to a polynucleotide, each separated by a stretch of contiguous nucleotides which are not complementary to adjacent nucleotides, can provide sufficient targeting specificity for mRNA.
- each stretch of complementary contiguous nucleotides is at least 4, 5, 6, 7, or 8 or more nucleotides in length.
- Noh- complementary intervening sequences are preferably 1, 2, 3, or 4 nucleotides in length.
- One skilled in the art can easily use the calculated melting point of an antisense-sense pair to determine the degree of mismatching which will be tolerated between a particular antisense oligonucleotide and a particular polynucleotide sequence.
- Antisense oligonucleotides can be modified without affecting their ability to hybridize to a polynucleotide of the invention. These modifications can be internal or at one or both ends of the antisense molecule.
- internucleoside phosphate linkages can be modified by adding cholesteryl or diamine moieties with varying numbers of carbon residues between the amino groups and terminal ribose.
- Modified bases and/or sugars such as arabinose instead of ribose, or a 3', 5 '-substituted oligonucleotide in which the 3' hydroxyl group or the 5' phosphate group are substituted, also can be employed in a modified antisense oligonucleotide.
- modified oligonucleotides can be prepared by methods well known in the art. See, e.g., Agrawal et al., (1992) Trends Biotechnol, 10:152-158; Uhlmann et al., (1990) Chem. Rev., 90:543-584; Uhlmann et al., (1987) Tetrahedron. Lett., 215:3539-3542.
- Ribozymes are RNA molecules with catalytic activity. See, e.g., Cech, (1987) Science, 236:1532-1539; Cech, (1990) Ann. Rev. Biochem., 59:543-568; Cech, (1992) Curr. Opin. Struct. Biol, 2:605-609; Couture & Stinchcomb, (1996) Trends Genet., 12:510-515. Ribozymes can be used to inhibit gene function by cleaving an RNA sequence, as is known in the art (e.g., Haseloff et al., U.S. Patent 5,641,673).
- the mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage.
- Examples include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of specific nucleotide sequences.
- the coding sequence of a polynucleotide of the invention can be used to generate ribozymes which will specifically bind to mRNA transcribed from the polynucleotide.
- cleavage activity of ribozymes can be targeted to specific RNAs by engineering a discrete "hybridization" region into the ribozyme.
- the hybridization region contains a sequence complementary to the target RNA and thus specifically hybridizes with the target (see, e.g., Gerlach et al., EP 321,201).
- Specific ribozyme cleavage sites within a RNA target can be identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides co ⁇ esponding to the region of the target RNA containing the cleavage site can be evaluated for secondary structural features which may render the target inoperable. Suitability of candidate RNA targets also can be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays. The nucleotide sequences shown in SEQ ID NOs: 1-55 and their complements provide sources of suitable hybridization region sequences.
- hybridizing and cleavage regions of the ribozyme can be integrally related such that upon hybridizing to the target RNA through the complementary regions, the catalytic region of the ribozyme can cleave the target.
- Ribozymes can be introduced into cells as part of a DNA construct. Mechanical methods, such as microinjection, liposome-mediated transfection, electroporation, or calcium phosphate precipitation, can be used to introduce a ribozyme-containing DNA construct into cells in which it is desired to decrease polynucleotide expression. Alternatively, if it is desired that the cells stably retain the DNA construct, the construct can be supplied on a plasmid and maintained as a separate element or integrated into the genome of the cells, as is known in the art.
- a ribozyme-encoding DNA construct can include transcriptional regulatory elements, such as a promoter element, an enhancer or UAS element, and a transcriptional terminator signal, for controlling transcription of ribozymes in the cells.
- ribozymes can be engineered so that ribozyme expression will occur in response to factors which induce expression of a target gene. Ribozymes also can be engineered to provide an additional level of regulation, so that destruction of mRNA occurs only when both a ribozyme and a target gene are induced in the cells.
- Pathological conditions or susceptibility to pathological conditions can be diagnosed using methods of the invention. Testing for expression of a polynucleotide of the invention or for the presence of the polynucleotide product can co ⁇ elate with the severity of the condition and can also indicate appropriate treatment. For example, the presence or absence of a mutation in a polynucleotide of the invention can be determined and a pathological condition or a susceptibility to a pathological condition is diagnosed based on the presence or absence of the mutation.
- an alteration in expression of a polypeptide encoded by a polynucleotide of the invention can be detected, where the presence of an alteration in expression of the polypeptide is indicative of the pathological condition or susceptibility to the pathological condition.
- the alteration in expression can be an increase in the amount of expression or a decrease in the amount of expression.
- a first biological sample from a patient suspected of having a pathological condition is obtained along with a second sample from a suitable comparable control source.
- a biological sample can comprise saliva, blood, cerebrospinal fluid, amniotic fluid, urine, feces, or tissue, such as gastrointestinal tissue.
- a suitable control source can be obtained from one or more mammalian subjects that do not have the pathological condition.
- the average concentrations and distribution of a polynucleotide or polypeptide of the invention can be determined from biological samples taken from a representative population of mammalian subjects, wherein the mammalian subjects are the same species as the subject from which the test sample was obtained.
- the amount of at least one polypeptide encoded by a polynucleotide of the invention is determined in the first and second sample.
- the amounts of the polypeptide in the first and second samples are compared.
- a patient is diagnosed as having a pathological condition if the amount of the polypeptide in the first sample is greater than or less than the amount of the polypeptide in the second sample.
- the amount of polypeptide in the first sample falls in the range of samples taken from a representative group of patients with the pathological condition.
- nucleic acid molecule comprising a nucleotide sequence which is at least 80%o, preferably at least 85%>, more preferably at least 90%, most preferably at least 95%> identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NOs: 1-55.
- nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NOs:l-55 in the range of positions beginning with the nucleotide at about the position of the 5' nucleotide of the clone sequence and ending with the nucleotide at about the position of the 3' nucleotide of the clone sequence.
- nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NOs: 1-55 in the range of positions beginning with the nucleotide at about the position of the 5' nucleotide of the start codon and ending with the nucleotide at about the position of the 3' nucleotide of the clone sequence as defined for SEQ ID NOs: 1-55.
- nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ED NOs: 1-55 in the range of positions beginning with the nucleotide at about the position of the 5' nucleotide of the first amino acid of the signal peptide and ending with the nucleotide at about the position of the 3' nucleotide of the clone sequence as defined for SEQ ID NOs:l-55.
- nucleic acid molecule comprising a nucleotide sequence which is at least 95%> identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NOs:l-55.
- nucleic acid molecule comprising a nucleotide sequence which is at least 95%> identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NOs:l-55.
- a further prefe ⁇ ed embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95%> identical to the nucleotide sequence of SEQ ID NOs:l-55 beginning with the nucleotide at about the position of the 5' nucleotide of the first amino acid of the signal peptide and ending with the nucleotide at about the position of the 3' nucleotide of the clone sequence as defined for SEQ ED NOs: 1-55.
- a further prefe ⁇ ed embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NOs: 1-55.
- nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.
- a further prefe ⁇ ed embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95%> identical to a sequence of at least 35 contiguous nucleotides in a sequence selected from the group consisting of a nucleotide sequence of SEQ ED NOs: 1 -55, which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95%> identical to said selected sequence.
- step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group.
- step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group.
- the nucleic acid molecules can comprise DNA molecules or RNA molecules.
- a further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 35 contiguous nucleotides in a sequence selected from the group consisting of a nucleotide sequence of SEQ ID NOs: 1-55.
- Also prefe ⁇ ed is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95%> identical to a sequence of at least 35 contiguous nucleotides in a sequence selected from the group consisting of a nucleotide sequence of SEQ ID NOs: 1-55.
- the method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 35 contiguous nucleotides in a sequence selected from said group.
- composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95%> identical to a sequence of at least 35 contiguous nucleotides in a sequence selected from the group consisting of a nucleotide sequence of SEQ ID NOs: 1-55.
- the nucleic acid molecules can comprise DNA molecules or RNA molecules.
- Also prefe ⁇ ed is an isolated polypeptide comprising an amino acid sequence at least 90%) identical to a sequence of at least about 10 contiguous amino acids in an amino acid sequence translated from SEQ ED NOs:l-55.
- polypeptide wherein said sequence of contiguous amino acids is included in amino acids in an amino acid sequence translated from SEQ ED NOs: 1-55, in the range of positions beginning with the residue at about the position of the first amino acid of the secreted portion and ending with the residue at about the last amino acid of the open reading frame.
- Also prefe ⁇ ed is an isolated polypeptide comprising an amino acid sequence at least 95%o identical to a sequence of at least about 30 contiguous amino acids in an amino acid sequence translated from SEQ ID NOs: 1-55.
- an isolated polypeptide comprising an amino acid sequence at least 95%) identical to a sequence of at least about 100 contiguous amino acids in an amino acid sequence translated from SEQ JD NOs: 1-55.
- a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90%> identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of amino acid sequences translated from SEQ ID NOs: 1-55, which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.
- step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90%> identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of amino acid sequences translated from SEQ ID NOs: 1-55.
- Also prefe ⁇ ed is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group. Also prefe ⁇ ed is a method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90%> identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of amino acid sequences translated from SEQ ID NOs: 1-55.
- Also prefe ⁇ ed is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90%> identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.
- Also prefe ⁇ ed is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of amino acid sequences translated from SEQ ID NOs: 1-55.
- the step of detecting said polypeptide molecules includes using an antibody.
- nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of amino acid sequences translated from SEQ ED NOs: 1-55.
- nucleic acid molecule wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host. Also prefe ⁇ ed is an isolated nucleic acid molecule, wherein said nucleotide sequence encodes a polypeptide comprising an amino acid sequence selected from the group consisting of amino acid sequences translated from SEQ ID NOs:l-55.
- prefe ⁇ ed is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also prefe ⁇ ed is the recombinant vector produced by this method. Also prefe ⁇ ed is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.
- Also prefe ⁇ ed is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also prefe ⁇ ed is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of amino acid sequences translated from SEQ ID NOs:l-55. The isolated polypeptide produced by this method is also prefe ⁇ ed.
- Also prefe ⁇ ed is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.
- the present invention also includes a diagnostic system, preferably in kit form, for assaying for the presence of the polypeptide of the present invention in a body sample, such as brain tissue, cell suspensions or tissue sections; or a body fluid sample, such as CSF, blood, plasma or serum, where it is desirable to detect the presence, and preferably the amount, of the polypeptide of this invention in the sample according to the diagnostic methods described herein.
- a body sample such as brain tissue, cell suspensions or tissue sections
- a body fluid sample such as CSF, blood, plasma or serum
- a nucleic acid molecule can be used as a probe (i.e., an oligonucleotide) to detect the presence of a polynucleotide of the present invention, a gene co ⁇ esponding to a polynucleotide of the present invention, or a mRNA in a cell that is diagnostic for the presence or expression of a polypeptide of the present invention in the cell.
- the nucleic acid molecule probes can be of a variety of lengths from at least about 10, suitably about 10 to about 5000 nucleotides long, although they will typically be about 20 to 500 nucleotides in length. Hybridization methods are extremely well known in the art and will not be described further here.
- PCR primers are utilized in pairs, as is well known, based on the nucleotide sequence of the gene to be detected.
- the nucleotide sequence is a portion of the nucleotide sequence of a polynucleotide of the present invention.
- Particularly prefe ⁇ ed PCR primers can be derived from any portion of a DNA sequence encoding a polypeptide of the present invention, but are preferentially from regions which are not conserved in other cellular proteins.
- PCR primer pairs useful for detecting the genes co ⁇ esponding to the polynucleotides of the present invention and expression of these genes are described in the Examples, including the co ⁇ esponding Tables. Nucleotide primers from the co ⁇ esponding region of the polypeptides of the present invention described herein are readily prepared and used as PCR primers for detection of the presence or expression of the co ⁇ esponding gene in any of a variety of tissues.
- the diagnostic system includes, in an amount sufficient to perform at least one assay, a subject polypeptide of the present invention, a subject antibody or monoclonal antibody, and/or a subject nucleic acid molecule probe of the present invention, as a separately packaged reagent.
- a diagnostic system preferably in kit form, is contemplated for assaying for the presence of the polypeptide of the present invention or an antibody immunoreactive with the polypeptide of the present invention in a body fluid sample.
- Such diagnostic kit would be useful for monitoring the fate of a therapeutically administered polypeptide of the present invention or an antibody immunoreactive with the polypeptide of the present invention.
- the system includes, in an amount sufficient for at least one assay, a polypeptide of the present invention and/or a subject antibody as a separately packaged immunochemical reagent.
- a package refers to a solid matrix or material such as glass, plastic (e.g., polyethylene, polypropylene, or polycarbonate), paper, foil and the like capable of holding within fixed limits a polypeptide, polyclonal antibody, or monoclonal antibody of the present invention.
- a package can be a glass vial used to contain milligram quantities of a contemplated polypeptide or antibody or it can be a microtiter plate well to which microgram quantities of a contemplated polypeptide or antibody have been operatively affixed (i.e., linked) so as to be capable of being immunologically bound by an antibody or antigen, respectively.
- Instructions for use typically include a tangible expression describing the reagent concentration or at least one assay method parameter, such as the relative amounts of reagent and sample to be admixed, maintenance time periods for reagent/ sample admixtures, temperature, buffer conditions, and the like.
- a diagnostic system of the present invention preferably also includes a label or indicating means capable of signaling the formation of an immunocomplex containing a polypeptide or antibody molecule of the present invention.
- complex refers to the product of a specific binding reaction such as an antibody-antigen or receptor-ligand reaction.
- exemplary complexes are immunoreaction products.
- label and "indicating means” in their various grammatical forms refer to single atoms and molecules that are either directly or indirectly involved in the production of a detectable signal to indicate the presence of a complex. Any label or indicating means can be linked to or inco ⁇ orated in an expressed protein, polypeptide, or antibody molecule that is part of an antibody or monoclonal antibody composition of the present invention or used separately, and those atoms or molecules can be used alone or in conjunction with additional reagents. Such labels are themselves well-known in clinical diagnostic chemistry and constitute a part of this invention only insofar as they are utilized with otherwise novel proteins methods and/or systems.
- the labeling means can be a fluorescent labeling agent that chemically binds to antibodies or antigens without denaturing them to form a fluorochrome (dye) that is a useful immunofluorescent tracer.
- Suitable fluorescent labeling agents are fluorochromes such as fluorescein isocyanate (FIC), fluorescein isothiocyanate (FITC), 5-dimethylamine-l- naphthalenesulfonyl chloride (DANSC), tetramethylrhodamine isothiocyanate (TRITC), lissamine, rhodamine 8200 sulphonyl chloride (RB 200 SC) and the like.
- fluorochromes such as fluorescein isocyanate (FIC), fluorescein isothiocyanate (FITC), 5-dimethylamine-l- naphthalenesulfonyl chloride (DANSC), tetramethylrhodamine isothiocyanate (TRI
- the indicating group is an enzyme, such as horseradish peroxidase (HRP), glucose oxidase, or the like.
- HRP horseradish peroxidase
- glucose oxidase or the like.
- additional reagents are required to visualize the fact that a receptor-ligand complex (immunoreactant) has formed.
- additional reagents for HRP include hydrogen peroxide and an oxidation dye precursor such as diaminobenzidine.
- An additional reagent useful with glucose oxidase is 2,2'-amino-di-(3- ethyl-benzthiazoline-G-sulfonic acid) (ABTS).
- Radioactive elements are also useful labeling agents and are used illustratively herein.
- An exemplary radiolabeling agent is a radioactive element that produces gamma ray emissions.
- Elements which themselves emit gamma rays such as 124 1, 125 1, 128 1, 132 I and 51 Cr represent one class of gamma ray emission-producing radioactive element indicating groups. Particularly prefe ⁇ ed is 125 I.
- Another group of useful labeling means are those elements such as U C, 18 F, 15 O and 13 N which themselves emit positrons. The positrons so emitted produce gamma rays upon encounters with electrons present in the animal's body.
- a beta emitter such 1 ⁇ 'indium or 3 H.
- the linking of labels or labeling of polypeptides and proteins is well known in the art.
- antibody molecules produced by a hybridoma can be labeled by metabolic inco ⁇ oration of radioisotope-containing amino acids provided as a component in the culture medium (see, e.g., Galfre et al., Meth. Enzymol, 73:3-46 (1981)).
- the techniques of protein conjugation or coupling through activated functional groups are particularly applicable (see, e.g., Aurameas, et al., Scand. J. Immunol, Vol. 8 Suppl. 7:7-23 (1978); Rodwell et al., Biotech., 3:889-894 (1984); and U.S. Patent No. 4,493,795).
- the diagnostic systems can also include, preferably as a separate package, a specific binding agent.
- a "specific binding agent” is a molecular entity capable of selectively binding a reagent species of the present invention or a complex containing such a species, but is not itself a polypeptide or antibody molecule composition of the present invention.
- Exemplary specific binding agents are second antibody molecules, complement proteins or fragments thereof, S aureus protein A, and the like.
- the specific binding agent binds the reagent species when that species is present as part of a complex.
- the specific binding agent is labeled.
- the agent is typically used as an amplifying means or reagent.
- the labeled specific binding agent is capable of specifically binding the amplifying means when the amplifying means is bound to a reagent species-containing complex.
- the diagnostic kits of the present invention can be used in an "ELISA" format to detect the quantity of the polypeptide of the present invention in a sample.
- ELISA refers to an enzyme-linked immunosorbent assay that employs an antibody or antigen bound to a solid phase and an enzyme-antigen or enzyme-antibody conjugate to detect and quantify the amount of an antigen present in a sample.
- a description of the ELISA technique is found in Sites et al., Basic and Clinical Immunology, 4 th Ed., Chap. 22, Lange Medical Publications, Los Altos, CA (1982) and in U.S. Patent No. 3,654,090; U.S. Patent No. 3,850,752; and U.S. Patent No.
- a polypeptide of the present invention an antibody or a monoclonal antibody of the present invention can be affixed to a solid matrix to form a solid support that comprises a package in the subject diagnostic systems.
- a reagent is typically affixed to a solid matrix by adso ⁇ tion from an aqueous medium, although other modes of affixation applicable to proteins and polypeptides can be used that are well known to those skilled in the art. Exemplary adso ⁇ tion methods are described herein.
- Useful solid matrices are also well known in the art. Such materials are water insoluble and include the cross-linked dextran available under the trademark SEPHADEX from
- Pharmacia Fine Chemicals Pieriscataway, NJ
- agarose polystyrene beads of about 1 micron ( ⁇ m) to about 5 millimeters (mm) in diameter available from several suppliers (e.g., Abbott Laboratories, Chicago, IL), polyvinyl chloride, polystyrene, cross-linked polyacrylamide, nitrocellulose- or nylon-based webs (sheets, strips or paddles) or tubes, plates or the wells of a microtiter plate, such as those made from polystyrene or polyvinylchloride.
- the reagent species, labeled specific binding agent, or amplifying reagent of any diagnostic system described herein can be provided in solution, as a liquid dispersion or as a substantially dry power, e.g., in lyophilized form.
- the indicating means is an enzyme
- the enzyme's substrate can also be provided in a separate package of a system.
- a solid support such as the before-described microtiter plate and one or more buffers can also be included as separately packaged elements in this diagnostic assay system.
- packaging materials discussed herein in relation to diagnostic systems are those customarily utilized in diagnostic systems.
- RNAs which expression is regulated by fatty lesion development caused by hypercholesterolemia, regulated by lercanidipine treatment, or regulated by hypercholesterolemia and reversed by lercanidipine treatment were identified.
- lercanidipine refers to the racemic mixture of lercanidipine hydrochloride
- (R)-lercanidipine refers to the (R)-enantiomer of lercanidipine hydrochloride
- Day 14 + (R)- lercanidipine mRNA samples were prepared from rabbits given a cholesterol diet for two weeks and treated with 3 mg/kg/week (R)-lercanidipine for four weeks.
- the daily doses of cholesterol were given in the morning (at 08.00 hours) each mixed in 20g of food pellets. Normal chow, up to 150g, was added after all the cholesterol- rich diet was eaten (usually within 30 minutes).
- the hydrochloride salt of lercanidipine or (R)- lercanidipine (Recordati, Milano, Italy) was administered subcutaneously as a solution in 50%> propylene glycol.
- the doses of lercanidipine utilized here did not affect arterial blood pressure. Animals had free access to water and were kept in a 12 hour light-dark cycle. Blood was drawn from the central ear artery at day 29 after treatment, started in order to monitor the lercanidipine plasma level at 24 hour post-dose.
- lercanidipine used were determined from preliminary kinetic studies. In rabbits, the subcutaneous administration of 3 and 1 mg/kg lercanidipine resulted in plasma levels of 3.2 and 0.5 mg/kg respectively, after 7 days from the administration.
- Total serum cholesterol was measured at sacrifice by the enzymatic procedure described in Catapano et al., Ann. N. Y. Acad. Sci., 522:519-521 (1988).
- High density lipoprotein (HDL) cholesterol was determined by the same method after very low density and low density lipoproteins (LDL) precipitation with phosphotungstic acid (Catapano et al. (1988), supra).
- LDL low density lipoproteins
- Aorta mRNAs were prepared in the following manner.
- the poly A+ mRNA was prepared using standard methods of polyA selection known in the art (Schriber et al., J. Mol. Biol, 142:93-116 (1980)).
- the isolated mRNA was analyzed using a method of simultaneous sequence-specific identification of mRNAs known as TOGA, described in U.S. Patent No. 5,459,037 and U.S. Patent No. 5,807,680, hereby inco ⁇ orated herein by reference.
- the TOGA method further comprised an additional PCR step performed using a mixture of four 5' PCR primers and cDNA templates prepared from a population of antisense cRNAs.
- a final PCR step that used a mixture of 256 5' PCR primers produced PCR products that were cDNA fragments that co ⁇ esponded to the 3 '-region of the starting mRNA population.
- the produced PCR products were then identified by: (a) the initial 5' sequence comprising the sequence remainder of the recognition site of the restriction endonuclease used to cut and isolate the 3' region plus the sequence of the preferably four parsing bases immediately 3' to the remainder of the recognition site, preferably the sequence of the entire fragment; and (b) the length of the fragment.
- sequence and fragment length were used to compare the obtained PCR products to a database of known polynucleotide sequences. Since the length of the obtained PCR products includes known vector sequences at the 5' and 3' ends of the insert, the sequence of the insert provided in the sequence listing is shorter than the fragment length that forms part of the digital address.
- the method yields Digital Sequence Tags (DSTs), that is, polynucleotides that are expressed sequence tags of the 3' end of mRNAs. DSTs that showed changes in relative levels during fatty lesion development or as a result of lercanidipine treatment were selected for further study. The intensities of the laser-induced fluorescence of the labeled PCR products were compared across aortic sample isolated from control (no lercanidipine) or lercanidipine- treated rabbits at day 0, Day 14, and Week 8 of cholesterol treatment.
- DSTs Digital Sequence Tags
- double-stranded cDNA is generated from poly(A)-enriched cytoplasmic RNA extracted from the tissue samples of interest using an equimolar mixture of all 48 5'- biotinylated anchor primers of a set to initiate reverse transcription.
- One such suitable set is G-A-A-T-T-C-A-A-C-T-G-G-A-A-G-C-G-G-C-C-G-C-A-G-G-A-A-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-V-N-N (SEQ ID NO: 56), where V is A, C or G and N is A, C, G or T.
- One member of this mixture of 48 anchor primers initiates synthesis at a fixed position at the 3' end of all copies of each mRNA species in the sample, thereby defining a 3' endpoint for each species, resulting in biotinylated double-stranded cDNA.
- Each biotinylated double-stranded cDNA sample was cleaved with the restriction endonuclease Mspl, which recognizes the sequence CCGG.
- the resulting fragments of cDNA co ⁇ esponding to the 3' region of the starting mRNA were then isolated by capture of the biotinylated cDNA fragments on a streptavidin-coated substrate.
- Suitable streptavidin-coated substrates include microtitre plates, PCR tubes, polystyrene beads, paramagnetic polymer beads and paramagnetic porous glass particles.
- a prefe ⁇ ed streptavidin-coated substrate is a suspension of paramagnetic polymer beads (Dynal, Inc., Lake Success, NY).
- the cDNA fragment product was released by digestion with Notl, which cleaves at an 8-nucleotide sequence within the anchor primers but rarely within the mRNA-derived portion of the cDNAs.
- Plasmid preps (Qiagen) were made from the cDNA library of each sample under study.
- each library was digested with Mspl, which effects linearization by cleavage at several sites within the parent vector while leaving the 3' cDNA inserts and their flanking sequences, including the T3 promoter, intact.
- the product was incubated with T3 RNA polymerase (MEGAscript kit, Ambion) to generate antisense cRNA transcripts of the cloned inserts containing known vector sequences abutting the Mspl and Notl sites from the original cDNAs.
- T3 RNA polymerase MEGAscript kit, Ambion
- each of the cRNA preparations was processed in a three-step fashion.
- 250ng of cRNA was converted to first-strand cDNA using the 5' RT primer (A-G-G- T-C-G-A-C-G-G-T-A-T-C-G-G, (SEQ ID NO: 57).
- step two 400 pg of cDNA product was used as PCR template in four separate reactions with each of the four 5' PCR primers of the form G-G-T-C-G-A-C-G-G-T-A-T-C-G-G-N (SEQ ID NO: 58), each paired with a "universal" 3' PCR primer G-A-G-C-T-C-C-A-C-C-G-C-G-G-G-T (SEQ ID NO: 59).
- step three the product of each subpool was further divided into 64 subsubpools (2ng in 20 ⁇ l) for the second PCR reaction, with 100 ng each of the fluoresceinated "universal" 3' PCR primer, the oligonucleotide (SEQ ID NO: 59) conjugated to 6-FAM and the appropriate 5' PCR primer of the foim C-G-A-C-G-G-T-A-T-C-G-G-N-N-N-N (SEQ ID NO: 60), using a program that included an annealing step at a temperature X slightly above the T m of each 5' PCR primer to minimize artifactual mispriming and promote high fidelity copying.
- Each polymerase chain reaction step was performed in the presence of TaqStart antibody (Clontech).
- Table 1 is a summary of the expression levels of 594 mRNAs determined from cDNA. These cDNA molecules are identified by their digital address, that is, a partial 5' terminus nucleotide sequence comprising the remainder of the Mspl site and the four parsing bases for the 5' PCR primer of each subsubpool coupled with the length of the molecule, as well as the relative amount of the molecule produced in control and lercanidipine-treated animals at different time intervals after cholesterol treatment.
- the 5' terminus partial nucleotide sequence is determined by the recognition site for Mspl and the nucleotide sequence of the parsing bases of the 5' PCR primer used in the final PCR step.
- the length of the fragment was determined by inte ⁇ olation on a standard curve.
- the entry in Table 1 that describes a DNA molecule identified by the digital address Mspl AAGC 288 is further characterized as having a 5' terminus partial nucleotide sequence of CGGAAGC and a digital address length of 288 b.p.
- the DNA molecule identified as Mspl AAGC 288 is further described as being expressed at low levels in normal or control aorta at day 0 (no cholesterol, no lercanidipine) (251) and lercanidipine- treated aorta at day (no cholesterol, 3 mg/kg/week lercanidipine for 2 weeks) (215).
- the same DNA molecule is expressed at increasing levels after 14 days of cholesterol treatment (1008), which increase may be unaffected or slightly decreased by lercanidipine treatment (753) or R- lercanipidine treatment (872). The expression of this molecule is even greater at 8 weeks of cholesterol administration (1673) and does not appear to be affected by lercanidipine treatment (1733).
- a DNA molecule whose expression is up-regulated in a sustained manner by fatty lesion development induced by hypercholesterolemia has been identified.
- the DNA molecule identified as Mspl AAGC 288 (REC1_1) is described by its nucleotide sequence which co ⁇ esponds with SEQ ID NO: 1.
- the other DNA molecules identified in Table 1 by their Mspl digital addresses are further characterized by: (1) the level of gene expression in control rabbit aorta (no cholesterol, no lercanidipine); (2) the level of gene expression in aorta of lercanidipine- treated rabbits (no cholesterol, 3 mg/kg/week lercanidipine for 2 weeks); (3) the level of gene expression in control rabbit aorta at day 14 (14 day cholesterol diet, no lercanidipine); (4) the level of gene expression in aorta of lercanidine-treated rabbits at day 14 (14 day cholesterol diet, 3 mg/kg/week lercanidipine for 4 weeks); (5) the level of gene expression in aorta of (R)- lercanidipine-treated rabbits at day 14 (14 day cholesterol diet, 3 mg/kg/week (R)-lercanidipine for 4 weeks); (6) the level of gene expression in control rabbit aorta at week 8 (8 week cholesterol diet, no
- FIG. 1 shows the results of TOGA analysis using a 5' PCR primer with parsing bases AAGC (SEQ ED NO: 61)
- Figure 1 shows the PCR products produced from mRNA extracted from (A) normal control aorta (no cholesterol, no lercanidipine); (B) normal lercanidipine-treated aorta (no cholesterol, 3 mg/kg/week lercanidipine for 2 weeks); (C) control aorta at day 14 of cholesterol administration (no lercanidipine); (D) lercanidipine- treated aorta at day 14 of cholesterol administration (3 mg/kg/week lercanidipine for 4 weeks); (E) (R)-lercanidipine-treated aorta at day 14 of cholesterol administration (3 mg/kg/week (R)- lercanidipine for 4 weeks); (F) control aorta at week 8 of cholesterol administration (no lercanidipine); and (G) lercani
- the TOGA PCR product was sequenced using a modification of a direct sequencing methodology (Innis et al., Proc. Natl Acad. Sci., 85: 9436-9440 (1988)). PCR products co ⁇ esponding to DSTs were gel purified and PCR amplified again to inco ⁇ orate sequencing primers at the 5'- and 3'- ends. The sequence addition was accomplished through 5' and 3' ds-primers containing Ml 3 sequencing primer sequences (Ml 3 forward and Ml 3 reverse respectively) at their 5' ends, followed by a linker sequence and a sequence complementary to the DST ends.
- Ml 3 sequencing primer sequences Ml 3 forward and Ml 3 reverse respectively
- a master mix containing all components except the gel purified PCR product template was prepared, which contained sterile H 2 O, 10X PCR II buffer, lOmM dNTP, 25 mM MgCl 2 , AmpliTaq/Antibody mix (1.1 ⁇ g/ ⁇ l Taq antibody, 5 U/ ⁇ l AmpliTaq), 100 ng/ ⁇ l of 5' ds-primer (5' TCC CAG TCA CGA CGT TGT AAA ACG ACG GCT CAT ATG AAT TAG GTG ACC GAC GGT ATC GG 3', SEQ ID NO: 193), and 100 ng/ ⁇ l of 3' ds-primer (5' CAG CGG ATA ACA ATT TCA CAC AGG GAG CTC CAC CGC GGT GGC GGC C 3', SEQ ID NO: 194).
- 5' ds-primer 5' TCC CAG TCA CGA CGT TGT AAA ACG ACG GCT CAT ATG AAT T
- PCR was performed using the following program: 94°C, 4 minutes and 25 cycles of 94°C, 20 seconds; 65°C, 20 seconds; 72°C, 20 seconds; and 72°C 4 minutes.
- the resulting amplified PCR product was gel purified.
- the purified PCR product was sequenced using a standard protocol for ABI 3700 sequencing. Briefly, triplicate reactions in forward and reverse orientation (6 total reactions) were prepared, each reaction containing 5 ⁇ l of gel purified PCR product as template.
- the 3' sequencing primer was the sequence 5' GGT GGC GGC CGC AGG AAT TTT TTT TTT TTT TT 3', (SEQ ID NO: 197).
- PCR was performed using the following thermal cycling program: 96°C, 2 minutes and 29 cycles of 96°C, 15 seconds; 50°C, 15 seconds; 60°C, 4 minutes.
- PCR product of interest PCR primers were designed based on the sequences determined by direct sequencing, and PCR reactions were performed using the Nl TOGA PCR reaction products as substrate, as described above for the sequences cloned into the TOPO vector.
- oligonucleotides were synthesized with the sequence G-A-T-C-G-A-A-T-C extended at the 3' end with a partial Mspl site (C-G-G) and an additional 18 nucleotides adjacent to the partial Mspl site from the sequence determined by direct sequencing.
- the 5' PCR primer (SEQ ID NO: 145) was paired with the fluorescent labeled universal 3' PCR primer (SEQ ID NO:59) in PCR reactions with the Nl TOGA PCR reaction product as template(see Table 3). Some products, which were also differentially represented, appeared to migrate in positions that suggested that the products are novel based on sequence comparison data extracted from GenBank. In these cases, the PCR product was isolated, cloned into a TOPO vector (Invitrogen) and sequenced on both strands. In order to verify that the cloned product co ⁇ esponds to the TOGA peak of interest, PCR primers were designed based on the determined sequence and PCR was performed using the cDNA produced in the first PCR reaction as substrate.
- Oligonucleotides were synthesized with the sequence G-A-T-C-G-A-A- T-C extended at the 3' end with a partial Mspl site (C-G-G), and an additional 18 adjacent nucleotides from the cloned PCR product or DST.
- the 5' PCR primer was G-A-T-C-G-A-A-T-C-C-G-G-A-A-G-C-C-G-C-G-C- A-T-C-A-C-T-G-A-G (SEQ ID NO: 86).
- This 5' PCR primer was paired with the fluorescent labeled 3' PCR primer (SEQ ID NO: 59) in PCRs using the cDNA produced in the first PCR reaction as substrate.
- the primers for these studies are shown in Table 3, below.
- Table 4 shows differentially expressed products having the partial sequence expected from the indicated co ⁇ esponding sequence from GenBank as determined by the production of a PCR product using an extended 5' PCR primer.
- (B) shows the PCR products produced using the original PCR primers, SEQ ED NO: 61 and
- SEQ ED NO: 59 (compare to the panel in Figure IF).
- the upper panel shows the length (as peak position) of the PCR product derived from the isolated clone as described above using the PCR primers SEQ JD NO: 86 and SEQ ID NO: 59.
- the traces from the top and middle panels are overlaid, demonstrating that the PCR product of the isolated and sequenced novel clone is the same length as the original PCR
- REC1_1 As indicated by Table 1, the expression of REC1_1 is up-regulated in a sustained manner in the aorta of rabbits with fatty atherosclerotic lesion development caused by hypercholesterolemia. As shown in Tables 2 and 3, REC1_1 corresponds to a gene that encodes a tyrosine kinase binding protein. The REC1_1 molecule may be useful as a diagnostic marker to indicate a predisposition for altered lipid or cholesterol transport (hypercholesterolemia) which could lead to the development of atherosclerosis. The results of these analyses also indicate that REC1_1 may be a target substrate for the development of therapeutic agents.
- clones REC1_2, REC1_8 and REC1_11 are also up-regulated in the aorta of hypercholesterolemic rabbits in a sustained manner over the course of 8 weeks.
- Table 1 also shows that the expression of REC1 3 and REC1 10 is up-regulated early (at 14 days), but that the increased expression is not sustained.
- CTGA 390 (REC 1 10) shows a similar pattern of early up-regulated expression.
- Table 1 shows that the expression of several clones, REC1_6, REC1 13, and REC1_18, are up-regulated after a longer period of hypercholesterolemia.
- ATCC 176 REC1_6
- the above DST clones and at least part of the longer molecule co ⁇ esponding to the DST clones can be useful in diagnosing or montoring the presence of, or the development of, atherosclerosis in hypercholesterolemia
- the method of diagnosing or montoring the presence or development of atherosclerosis in hypercholesterolemia in a subject comprising detecting an alteration in expression of at least one polypeptide encoded by at least one polynucleotide selected from the group consisting of SEQ ED NO:l, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ED NO:8, SEQ ED NO:9, SEQ ID NO: 11 and SEQ ID NO.21.
- each DST examined the optimal annealing temperature and reagent conditions were determined for the co ⁇ esponding set of primers (see Table 25) based on results from a preliminary experiment. In eight separate reactions, each set of primers was assayed to find the optimal conditions by adjusting the following four parameters: primer concentration, dNTP concentration, MgCl 2 concentration, and number of Taq polymerase units. Once optimal conditions were determined, each DST was run in duplicate multiple simultaneous reactions which usually included at least four dilutions of template (cDNA library), plus control reactions lacking template, and six sequential data points for numbers of cycles.
- reactions were performed using "Hot Start” PCR with the Clontech TaqStart antibody system (Cat. #5400-1). Each reaction contained 1ml of the cDNA library dilution as template, determined amounts of AmpliTaq DNA polymerase (cat. #N808-0156), MgCl , dNTPs
- the annealing temperature was determined by adding five degrees to the average melting temperature. PCR was performed using the following program: 1) 95 degrees Celsius, 3 minutes; 2) 95 degrees Celsius, 30 seconds; 3) TM+5 degrees Celsius, 30 seconds; 4) 72 degrees Celsius, for a time dependent on target length at 16 bp/second; 5) repeat steps 2-4 33 more cycles; 6) 72 degrees Celsius, 3 minutes; 7) 14 degrees Celsius, forever.
- DST clone Recl l was one of the clones further evaluated by RT-PCR.
- the results of the quantified RT-PCR for Recl l are shown in Figure 6 and in Table 5 (normalized to the normocholesterolemic control value ("H2") at each time point).
- Figure 6 is a graphical representation of the results of RT-PCR using 20 pg of clone REC1_1 template, in which the amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- G filled squares
- F hypercholesterolemic plus lercanidipine racemate
- Figure 7 is a graphical representation of the results of RT-PCR using 500 pg of clone REC1_2 template, in which the amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- G filled squares
- F hypercholesterolemic plus lercanidipine racemate
- Figure 8 is a graphical representation of the results of RT-PCR using 500 pg of clone REC1 3 template, in which the amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2"), hypercholesterolemic (large filled squares, "E”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic large filled squares, "E”
- hypercholesterolemic eight weeks
- hypercholesterolemic plus lercanidipine racemate eight weeks
- Figure 9 is a graphical representation of the results of RT-PCR using 20 pg of clone REC1_8 template, in which the amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- G filled squares
- F hypercholesterolemic plus lercanidipine racemate
- Figure 10 is a graphical representation of the results of RT-PCR using 100 pg of clone REC1_10 template, in which the amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”) and hypercholesterolemic (filled squares, "E").
- Figure 11 is a graphical representation of the results of RT-PCR using 20 pg of clone RECl 6 template, in which the amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- G filled squares
- F hypercholesterolemic plus lercanidipine racemate
- Recl_6 is up-regulated in a sustained manner in the aorta of rabbits with fatty atherosclerotic lesion development caused by hypercholesterolemia.
- the expression pattern was verified in the RT-PCR study, which showed that the expression of Recl_6 at 8 weeks is elevated in hypercholesterolemic animals and somewhat more elevated in hypercholesterolemic animals receiving lercanidipine racemate.
- Figure 12 is a graphical representation of the results of RT-PCR using 100 pg of clone REC1 13 template, in which the amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- G filled squares
- F hypercholesterolemic plus lercanidipine racemate
- Recl_13 is up-regulated at 8 weeks in the aorta of rabbits with fatty atherosclerotic lesion development caused by hypercholesterolemia.
- the expression pattern was verified in the RT-PCR study, which showed that the expression of Recl_13 at 8 weeks is elevated both in hypercholesterolemic animals and in hypercholesterolemic animals receiving lercanidipine racemate.
- Figure 13 is a graphical representation of the results of RT-PCR using 20 pg of clone REC1_18 template, in which the amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- G filled squares
- F hypercholesterolemic plus lercanidipine racemate
- Recl_18 is up-regulated at 8 weeks in the aorta of rabbits with fatty atherosclerotic lesion development caused by hypercholesterolemia.
- the RT-PCR study showed that the expression of Recl_18 at 8 weeks is somewhat elevated both in hypercholesterolemic animals and in hypercholesterolemic animals receiving lercanidipine racemate.
- FIG. 3-5 An example of a polynucleotide that is down-regulated by fatty atherosclerotic lesion development is shown in Figures 3-5.
- a peak at about 282 is indicated, identified by digital address Mspl CACA 282 when a 5' PCR primer (SEQ JD NO: 66) was paired with SEQ ID NO: 59 to produce the panel of PCR products.
- the PCR product was cloned and sequenced as described in Example 1.
- oligonucleotides were synthesized with the sequence G-A-T-C-G-A-A-T-C extended at the 3' end with a partial Mspl site (C-G-G), and an additional 18 adjacent nucleotides from the cloned PCR product or DST.
- the 5' PCR primer was G-A-T-C-G-A-A-T-C-C-G-G-C-A-C-A-C-G-G-G-C-G-C-C-A-A-G-A-A-G-G-A-G-A (SEQ ID NO: 91).
- This 5' PCR primer was paired with the fluorescently labeled 3' PCR primer (SEQ ED NO: 59) in PCRs using the cDNA produced in the first PCR reaction as substrate.
- the middle panel shows the length (as peak position) of the PCR product derived from the isolated clone as described in Example 1 (using SEQ ID NO: 91 and SEQ ID NO: 59).
- the traces from the top and middle panels are overlaid, demonstrating that the PCR product of the isolated and sequenced novel clone is the same length as the original PCR product.
- the DNA molecule identified by the digital address Mspl CACA 282 (clone REC1_7), is further characterized as having a 5' terminus partial nucleotide sequence of CGGCACA and a digital address length of 282 b.p. REC1_7 is further described as being down-regulated during fatty lesion development.
- REC1_7 is expressed at higher levels in control aorta at day 0 (976, Figure 3A) and lercanidipine-treated aorta at day 0 (863, Figure 3B) than in control aorta at day 14 of cholesterol administration (787, Figure 3C), lercanidipine-treated aorta at day 14 of cholesterol administration (417, Figure 3D), and (R)- lercanidipine-treated aorta at day 14 (683, Figure 3E), as well as control aorta at week 8 of cholesterol administration (199, Figure 3F) and lercanidipine-treated aorta at week 8 of cholesterol administration (159, Figure 3G).
- the vertical index line indicates a PCR product of about 282 b.p. that shows greater expression in the aorta of rabbits fed a normal diet than those fed a high cholesterol diet.
- FIG. 5A-D The differential gene expression of REC1 7 is confirmed by the data shown in Figure 5A-D.
- Figure 5 A shows the TOGA analysis presented in Figure 3 for control aorta (no lercanidipine treatment) at day 0, day 14, and week 8 of cholesterol administration.
- Figure 5B shows the relative abundance of the REC1_7 product found in control aorta at day 0 and week 8 as determined from the TOGA graphical user interface (GUI) intensities.
- FIG.C shows the relative abundance of the REC1_7 product found in control aorta at day 0 and week 8, as determined by quantitative PCR performed from sample cDNA using internal primers of known REC1 7 sequence (SEQ ID NO: 124 and 125) to generate a gene-specific PCR fragment. The gel image below the graph visually depicts the REC1_7 products formed in the quantitative PCR reaction.
- REC1 7 is down-regulated in the aorta during fatty lesion development.
- REC1_5, REC1_16, REC1_17, REC1_19, REC1_20, and REC1_21 are down-regulated in the aorta of hypercholesterolemic rabbits in a sustained manner over the course of 8 weeks.
- TCGG 195 REC1 16 decreases over time under conditions of fatty lesion development induced by hypercholesterolemia.
- Table 1 also shows that the expression of REC1 15 is down-regulated early after fatty lesion development (at 14 days), but that the decreased expression is not sustained.
- the above DST clones and at least part of the longer molecule co ⁇ esponding to the DST clones can be useful in diagnosing or montoring the presence of, or the development of, atherosclerosis in hypercholesterolemia
- the method of diagnosing or montoring the presence or development of atherosclerosis in hypercholesterolemia in a subject comprising detecting an alteration in expression of at least one polypeptide encoded by at least one polynucleotide selected from the group consisting of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:13, SEQ ED NO:14, SEQ JD NO:16, SEQ ID NO:17 and SEQ ID NO:18.
- the present invention provides amethod of diagnosing or montoring the presence of development of atherosclerosis in hypercholesterolemia in a subject comprising comparing an alteration in expression of at least one polypeptide encoded by at least one polynucleotide selected from the group consisting of SEQ ED NO:l, SEQ ID NO:2, SEQ ID NO:3, SEQ JD NO:5, SEQ JD NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:l 1 and SEQ ID NO:21 to an alteration in expression of at least one polypeptide encoded by at least one polynucleotide selected from the group consisting of SEQ ID NO:4, SEQ ID NO:6, SEQ ED NO:13, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO: 17 and SEQ JD NO: 18.
- Example 3 above, were studied further using the RT-PCR techniques and analysis of Example
- Figure 14 is a graphical representation of the results of RT-PCR using 100 pg of clone REC1_7 template, in which the amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- G filled squares
- F hypercholesterolemic plus lercanidipine racemate
- Figure 15 is a graphical representation of the results of RT-PCR using 100 pg of clone REC1_5 template, in which the amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- G filled squares
- F hypercholesterolemic plus lercanidipine racemate
- Recl_5 is down-regulated at 8 weeks in the aorta of rabbits with fatty atherosclerotic lesion development caused by hypercholesterolemia.
- the expression pattern was verified in the RT-PCR study, which showed that the expression of Recl_5 at 8 weeks is decreased in hypercholesterolemic animals and in hypercholesterolemic animals receiving lercanidipine racemate at 28-30 cycles.
- Figure 16 is a graphical representation of the results of RT-PCR using 20 pg of clone REC1_16 template, in which the amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- G filled squares
- F hypercholesterolemic plus lercanidipine racemate
- Figure 17 is a graphical representation of the results of RT-PCR using 20 pg of clone REC1_17 template, in which the amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- G filled squares
- F hypercholesterolemic plus lercanidipine racemate
- Recl_17 is down-regulated at 8 weeks in the aorta of rabbits with fatty atherosclerotic lesion development caused by hypercholesterolemia.
- the expression pattern was verified in the RT-PCR study, which showed that the expression of Recl_17 at 8 weeks is decreased both in hypercholesterolemic animals and in hypercholesterolemic animals receiving lercanidipine.
- Figure 18 is a graphical representation of the results of RT-PCR using 100 pg of clone REC1_19 template, in which the amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- G filled squares
- F hypercholesterolemic plus lercanidipine racemate
- Recl_19 is substantially down-regulated at 8 weeks in the aorta of rabbits with fatty atherosclerotic lesion development caused by hyper-cholesterolemia.
- the expression pattern was verified in the RT-PCR study, which showed that the expression of Recl_19 at 8 weeks is decreased both in hypercholesterolemic animals and in hypercholesterolemic animals receiving lercanidipine.
- Figure 19 is a graphical representation of the results of RT-PCR using 20 pg of clone REC1 20 template, in which the amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- G filled squares
- F hypercholesterolemic plus lercanidipine racemate
- Figure 20 is a graphical representation of the results of RT-PCR using 20 pg of clone REC1_21 template, in which the amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled squares, "F”).
- Recl_21 is down-regulated by about tenfold at 8 weeks in the aorta of rabbits with fatty atherosclerotic lesion development caused by hyper-cholesterolemia.
- the expression pattern was verified in the RT-PCR study, which showed that the expression of Recl_21 at 8 weeks is substantially decreased in hypercholesterolemic animals receiving lercanidipine.
- Figure 21 is a graphical representation of the results of RT-PCR using 20 pg of clone REC1 12 template, in which the amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- G filled squares
- F hypercholesterolemic plus lercanidipine racemate
- Recl_12 is substantially down-regulated at 8 weeks in the aorta of rabbits with fatty atherosclerotic lesion development caused by hyper-cholesterolemia.
- the expression pattern was verified in the RT-PCR study, which showed that the expression of Recl_12 at 8 weeks is decreased both in hypercholesterolemic animals and in hypercholesterolemic animals receiving lercanidipine.
- TOGA analysis further identified several clones whose expression is affected by the administration of a racemic mixture of lercanidipine.
- the expression REC1 22 and REC1 24 is down-regulated in the aorta of normal and hypercholesterolemic rabbits treated with lercanidipine compared with untreated aorta.
- Clone REC1 22 (digital address TGGG 164) was obtained using the above-described TOGA analysis methods.
- the TOGA data was generated with a 5'-PCR primer (C-G-A-C-G- G-T-A-T-C-G-G-T-G-G-G, SEQ ED NO: 78) labeled with 6-carboxyfluorescein (6FAM, ABI) at the 5' terminus.
- PCR products were resolved by gel electrophoresis on 4.5%> acrylamide gels and the fluorescence data acquired on ABI377 automated sequencers. Data were analyzed using GeneScan software.
- the results of TOGA analysis indicate that the expression of REC1_22 is down-regulated by lercanidipine treatment.
- the expression of REC1_22 is greater (430) than the expression in lercanidipine-treated day 0 aorta (87).
- the expression is greater in normal aorta (381) than in lercanidipine-treated aorta (194).
- Figure 22 is a graphical representation of the results of RT-PCR using 20 pg of clone REC1 22 template, in which the amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”) and hypercholesterolemic plus lercanidipine R (-), eight weeks (filled squares, "D”).
- the TOGA data was generated with a 5'-PCR primer (C-G-A-C-G- G-T-A-T-C-G-G-C-C-G-G, SEQ ID NO: 79) labeled with 6-carboxyfluorescein (6FAM, ABI) at the 5' terminus.
- Table 1 indicates that the expression of REC1 24 is down-regulated by lercanidipine treatment. In normal day 0 aorta, the expression of RECl 24 is greater (449) than the expression in lercanidipine-treated day 0 aorta (122). Similarly, at day 14 of cholesterol diet, the expression is greater in normal aorta (273) than in lercanidipine-treated aorta (104).
- Figure 23 is a graphical representation of the results of RT-PCR using 100 pg of clone REC1 24 template, in which the amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2”) and hypercholesterolemic plus lercanidipine R (-), eight weeks (filled squares, "D”).
- Recl_24 is substantially down-regulated at 8 weeks in the aorta of rabbits with fatty atherosclerotic lesion development caused by hyper-cholesterolemia.
- the expression pattern was verified in the RT-PCR study, which showed that the expression of Recl_24 at 8 weeks is generally somewhat decreased in hypercholesterolemic animals receiving lercanidipine R (-) compared to normocholesterolemic animals.
- EXAMPLE 6 Identification and Characterization of Polynucleotides Differentially Regulated by Lercanidipine and (RVLercanidipine in Aorta TOGA analysis further identified several clones whose expression is affected by the administration of lercanidipine, but not (R)-lercanidipine. As discussed previously, lercanidipine has a chiral center that produces two enantiomers.
- Table 1 shows that the expression of REC1 28 is down-regulated in the aorta of rabbits treated with the racemic form of lercanidipine, but not with the (R)-enantiomer of lercanidipine.
- Clone REC1_28 (digital address CGGT 101) was obtained using the above- described TOGA analysis methods. As shown in Table 1, the results of TOGA analysis indicate that the expression of REC1 28 is down-regulated by lercanidipine treatment. At day 0, the expression of REC1_28 is greater in control aorta (1028) than in lercanidipine-treated aorta (229).
- Clones REC1 31, REC1_33, and REC1_34 are upregulated in the aorta of normal and hypercholesterolemic rabbits treated with lercanidipine compared with untreated aorta.
- the up-regulation is not observed in the aorta of rabbits treated with (R)-lercanidipine.
- Clones REC1_31 (digital address TGCA 210), REC1_33 (digital address CCGA 96), and REC1_34 (digital address CGGT 209) were obtained using the above-described TOGA analysis methods. As shown in Table 1, the results of TOGA analysis indicate that the expression of REC1_31 is up-regulated by lercanidipine treatment.
- the expression of clone REC1_33 is lower in control aorta (282) than in lercanidipine-treated aorta (1094).
- the expression is also lower in control aorta than in lercanidipine-treated aorta (842), but not in (R)-lercanidipine -treated aorta (170), suggesting that the up-regulation of REC1 33 may involve calcium antagonist activity.
- the expression of clone REC1 34 is lower in control aorta (20) than in lercanidipine-treated aorta (100) and at day 14 is lower in control aorta (40) than in lercanidipine-treated aorta (331) but not in (R)-lercanidipine -treated aorta (58).
- the data suggests the up-regulation of RECl -34 observed with lercanidipine treatment involves calcium antagonist activity.
- the above DST clones and at least part of the longer molecule corresponding to the DST clones can be useful in diagnosing or monitoring the effects of treating a subject with a dihydropyridine calcium antagonist.
- the invention provides a method of diagnosing or montoring the effects of treating a subject with a dihydropyridine calcium antagonist comprising detecting an alteration in expression of at least one polypeptide encoded by at least one polynucleotide selected from the group consisting of SEQ ED NO: 19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23 and SEQ ID NO:24.
- EXAMPLE 7 Identification and Characterization of Polynucleotides Which Cholesterol Effect is Reversed by Lercanidipine in Aorta
- TOGA analysis identified clones whose expression affected by the development of atherosclerotic fatty lesions is reversed by the treatment of lercanidipine.
- the expression REC1_36 is down-regulated during fatty lesion development.
- treatment with lercanidipine reverses the observed down-regulation in REC1_36 expression.
- the expression of cloneRECl_37 is up-regulated during fatty lesion development, which up-regulation is reversed by lercanidipine treatment.
- Clones REC1_36 (digital address TTAG 155) and REC1_37 (digital address TTCA 264) were obtained using the above-described TOGA analysis methods. As shown in Table 1, the results of TOGA analysis indicate that the expression of REC1_36 is down-regulated by fatty lesion development in untreated aorta. At day 0, the expression of REC1 36 in control aorta (no cholesterol, no lercanidipine) is higher (736) than the expression in control aorta exposed to cholesterol for 14 days (104) and 8 weeks (206). However, this down-regulation is partially reversed with lercanidipine treatment.
- clone REC1_36 was increased in aorta treated with lercanidipine (683) compared to control aorta (104).
- the expression of clone REC1 36 was increased in aorta treated with lercanidipine (400) compared to control aorta (206).
- Figure 24 is a graphical representation of the results of RT-PCR using 100 pg of clone REC1_36 template, in which the amount of PCR product (measured in arbitrary fluorescence units) is plotted against number of cycles, where polyA enriched mRNA was extracted from aortas of rabbits that were normocholesterolemic (filled diamonds, "H2"), hypercholesterolemic, eight weeks (filled squares, "G”) and hypercholesterolemic plus lercanidipine racemate, eight weeks (filled triangles, "F”).
- normocholesterolemic filled diamonds, "H2”
- hypercholesterolemic hypercholesterolemic
- G filled squares
- F hypercholesterolemic plus lercanidipine racemate
- Table 1 show that the expression of REC1 37 is up-regulated by fatty lesion development in untreated aorta.
- the expression of REC1 37 in control aorta no cholesterol, no lercanidipine
- the expression in control aorta exposed to cholesterol for 14 days (870) and 8 weeks (1462).
- the observed up-regulation in expression (870) is not affected by lercanidipine treatment (915), but is affected by treatment with the (R)-enantiomer of lercanidipine (42).
- the up-regulation (1462) is reversed by lercanidipine treatment (136).
- RT-PCR Reverse Transcriptase-Polymerase Chain Reaction
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Oscillators With Electromechanical Resonators (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17796300P | 2000-01-25 | 2000-01-25 | |
US177963P | 2000-01-25 | ||
PCT/US2001/002439 WO2001054651A2 (en) | 2000-01-25 | 2001-01-25 | Modulation of gene expression in formation of fatty atherosclerotic lesions |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1250431A2 true EP1250431A2 (en) | 2002-10-23 |
EP1250431A4 EP1250431A4 (en) | 2004-08-11 |
Family
ID=22650638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01905039A Withdrawn EP1250431A4 (en) | 2000-01-25 | 2001-01-25 | Modulation of gene expression in formation of fatty atherosclerotic lesions |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1250431A4 (en) |
AU (1) | AU2001232958A1 (en) |
CA (1) | CA2398563A1 (en) |
WO (1) | WO2001054651A2 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997030065A1 (en) * | 1996-02-16 | 1997-08-21 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of cardiovascular disease |
US5968770A (en) * | 1995-02-10 | 1999-10-19 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target |
-
2001
- 2001-01-25 EP EP01905039A patent/EP1250431A4/en not_active Withdrawn
- 2001-01-25 CA CA002398563A patent/CA2398563A1/en not_active Abandoned
- 2001-01-25 WO PCT/US2001/002439 patent/WO2001054651A2/en not_active Application Discontinuation
- 2001-01-25 AU AU2001232958A patent/AU2001232958A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5968770A (en) * | 1995-02-10 | 1999-10-19 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target |
WO1997030065A1 (en) * | 1996-02-16 | 1997-08-21 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of cardiovascular disease |
Non-Patent Citations (3)
Title |
---|
HELLER R A ET AL: "Discovery and analysis of inflammatory disease-related genes using cDNA microarrays" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, no. 94, pages 2150-2155, XP002076789 ISSN: 0027-8424 * |
See also references of WO0154651A2 * |
WANG XINKANG ET AL: "The use of mRNA differential display for discovery of novel therapeutic targets in cardiovascular disease" CARDIOVASCULAR RESEARCH, vol. 35, no. 3, September 1997 (1997-09), pages 414-421, XP002281448 ISSN: 0008-6363 * |
Also Published As
Publication number | Publication date |
---|---|
EP1250431A4 (en) | 2004-08-11 |
WO2001054651A3 (en) | 2002-01-17 |
WO2001054651A2 (en) | 2001-08-02 |
CA2398563A1 (en) | 2001-08-02 |
AU2001232958A1 (en) | 2001-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2003514510A (en) | Human pancreas and pancreatic cancer-related gene sequences and polypeptides | |
JP2002532083A (en) | 47 human secreted proteins | |
CA2394753A1 (en) | Human protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies | |
CA2392693A1 (en) | Four disulfide core domain-containing (fdcd) polynucleotides, polypeptides, and antibodies | |
US20030215817A1 (en) | Modulation of gene expression in formation of fatty atherosclerotic lesions | |
AU2001232958A1 (en) | Modulation of gene expression in formation of fatty atherosclerotic lesions | |
AU7354700A (en) | Human neuropeptide receptor | |
JP2003510074A (en) | 26 human secreted proteins | |
JP2003520030A (en) | 28 human secreted proteins | |
WO2001029179A2 (en) | Regulation of gene expression by neuromodulators | |
CA2389110A1 (en) | Regulation of gene expression by neuroleptic agents | |
WO2002042420A2 (en) | Modulation of gene expression during intimal hyperplasia of the carotid artery | |
WO2000077166A2 (en) | Gene expression modulated in gastrointestinal inflammation | |
WO2002031114A2 (en) | Gene expression modulated in ileitis | |
WO2001012647A1 (en) | Gene expression modulated in ataxia telangiectasia tumorgenesis | |
US20060142233A1 (en) | Gene expression and genetic changes implicated in alcoholism | |
JP2003520031A (en) | 28 human secreted proteins | |
WO2002081726A2 (en) | Modulation of gene expression in mouse genetic models of atherosclerosis | |
WO2001034770A2 (en) | Gene expression modulated by activation of microglia or macrophages | |
WO2002031116A2 (en) | Gene expression modulated in spontaneous inflammatory bowel disease | |
JP2004506402A (en) | 48 human secretory proteins | |
WO2003091390A2 (en) | Regulation of gene expression by neuromodulators and discovery of a novel ngf-induced protein termed pincher | |
WO2002022783A2 (en) | Liver gene expression associated with the inhibition of hbv replication or transcription | |
WO2000028013A2 (en) | Gene expression modulated by activation of microglia or macrophages | |
JP2003512063A (en) | 37 human secreted proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020806 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
19U | Interruption of proceedings before grant |
Effective date: 20040407 |
|
19W | Proceedings resumed before grant after interruption of proceedings |
Effective date: 20041102 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040628 |
|
19W | Proceedings resumed before grant after interruption of proceedings |
Effective date: 20051004 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NEUROME, INC. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20060801 |